

1 UNITED STATES DISTRICT COURT
2 FOR THE NORTHERN DISTRICT OF OHIO
3 EASTERN DIVISION
4

5 -----x MDL No. 2804
6 IN RE: NATIONAL PRESCRIPTION) Case No.
7 OPIATE LITIGATION) 1:17-MD-2804
8 APPLIES TO ALL CASES) Hon. Dan A. Polster
9 -----x

10 HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER
11 CONFIDENTIALITY REVIEW
12

VIDEOTAPED DEPOSITION OF ELIZABETH T. TATUM

13
14 WASHINGTON, D.C.

TUESDAY, DECEMBER 11, 2018

15
16 9:27 A.M.
17
18
19
20
21
22
23

24 Reported by: Leslie A. Todd

1 Deposition of ELIZABETH T. TATUM, held at
2 the law offices of:

3

4

5 Motley Rice LLC

6 401 9th Street, NW

7 Suite 1001

8 Washington, DC 20004

9

10

11

12

13 Pursuant to notice, before Leslie Anne Todd,
14 Court Reporter and Notary Public in and for the
15 District of Columbia, who officiated in
16 administering the oath to the witness.

17

18

19

20

21

22

23

24

1 A P P E A R A N C E S

2

3 ON BEHALF OF THE PLAINTIFFS:

4 KRISTA BAISCH, ESQUIRE

5 ERIN DICKINSON, ESQUIRE

6 CRUEGER DICKINSON LLC

7 4532 North Oakland Avenue

8 Whitefish Bay, Wisconsin 53211

9 (414) 210-4367

10

11 ON BEHALF OF THE WITNESS:

12 SHERIDAN ENGLAND, ESQUIRE

13 S.L. ENGLAND, PLLC

14 1050 Connecticut Avenue, N.W.

15 5th Floor

16 Washington, D.C. 20036

17 (202) 572-1020

18

19 ON BEHALF OF CARDINAL HEALTH:

20 BRAD MASTERS, ESQUIRE

21 WILLIAMS & CONNOLLY LLP

22 725 Twelfth Street, N.W.

23 Washington, D.C. 20005

24 (202) 434-5000

1 APPEARANCES (Continued):

2

3 ON BEHALF OF McKESSON CORPORATION:

4 MICHELLE YOCUM, ESQUIRE

5 COVINGTON & BURLING, LLP

6 One CityCenter

7 850 Tenth Street, NW

8 Washington, DC 20001-4956

9 (202) 662-5103

10

11 ON BEHALF OF ENDO PHARMACEUTICALS, INC. and

12 ENDO HEALTH SOLUTIONS, INC., and PAR

13 PHARMACEUTICAL:

14 ANGELA R. VICARI, ESQUIRE

15 SEAN MCCORMICK, ESQUIRE (Telephonically)

16 ARNOLD & PORTER KAY SCHOLER, LLP

17 250 West 55th Street

18 New York, NY 10019-9710

19 (212) 836-8000

20

21

22

23

24

1 APPEARANCES (Continued):

2

3 ON BEHALF OF AMERISOURCEBERGEN:

4 MOLLY Q. CAMPBELL, ESQUIRE (Telephonically)

5 REED & SMITH, LLP

6 1301 K Street, N.W.

7 Suite 1000 - East Tower

8 Washington, D.C. 20005

9 (202) 414-9173

10

11 ON BEHALF OF MALLINCKRODT PHARMACEUTICALS and

12 SPECGX, LLC:

13 JOSHUA GOLDSTEIN, ESQUIRE

14 ROPES & GRAY, LLP

15 800 Boylston Street

16 Boston, Massachusetts 02199-3600

17 (617) 951-7000

18

19

20

21

22

23

24

1 APPEARANCES (Continued):

2

3 ON BEHALF OF PURDUE PHARMA:

4 JENNA C. NEWMARK, ESQUIRE

5 DECHERT, LLP

6 Three Bryant Park

7 1095 Avenue of the Americas

8 New York, NY 10036-6797

9 (212) 649-8723

10

11 ALSO PRESENT:

12 DANIEL HOLMSTOCK (Videographer)

13

14

15

16

17

18

19

20

21

22

23

24

1 C O N T E N T S

2	EXAMINATION OF ELIZABETH T. TATUM	PAGE
3	By Ms. Baisch	11, 155
4	By Ms. Vicari	144
5	By Mr. Masters	153

6

7

8 E X H I B I T S

9 (Attached to transcript)

10	AAPM-TATUM DEPOSITION EXHIBITS	PAGE
11	No. 1 Subpoena to Testify at a Deposition	
12	in a Civil Action	16
13	No. 2 Article entitled "The Use of	
14	Opioids for the Treatment of	
15	Chronic Pain"	73
16	No. 3 E-mail string re ASIPP Meeting	
17	Update, Bates PPLP004025116 to	
18	004025118	88
19	No. 4 E-mail string re Confirmation:	
20	Jan 31-Feb 1 Meeting, Bates	
21	CHI_000970678 to 000970698	93
22	No. 5 E-mail re Announcement: Establishment	
23	Of the AAPM Foundation, Bates	
24	PLLP004349978 to 004349981	96

1	E X H I B I T S (Continued)		
2	(Attached to transcript)		
3	TATUM DEPOSITION EXHIBITS		PAGE
4	No. 6	E-mail string re Safe Opioid	
5		Prescribing Curriculum, Bates	
6		PPLP004352212 to 004352216	100
7	No. 7	E-mail string re AAPM Grant,	
8		Bates END00446489 to 00446491	103
9	No. 8	E-mail re AAPM Safe Opioid	
10		Prescribing Initiative, Bates	
11		ALLERGAN_MDL_00498466	104
12	No. 9	E-mail string re Grant Submission:	
13		AAPM Safe Opioid Prescribing	
14		Initiative, Bates MNK-T1_0004298965	
15		to 0004298985	106
16	No. 10	E-mail string re Initial	
17		teleconference: SOPrescribing	
18		Planning Committee, Bates	
19		PPLP004345388 to 004345444	108
20	No. 11	E-mail string re Initial	
21		teleconference: SOPrescribing	
22		Planning Committee, Bates	
23		PPLP004346926 to 004346930	111
24			

1	E X H I B I T S (Continued)		
2	(Attached to transcript)		
3	AAPM-TATUM DEPOSITION EXHIBITS		PAGE
4	No. 12	E-mail string re Grant contacts:	
5		SOPrescribing Planning Committee,	
6		Bates PPLP004345177 to 004345181	116
7	No. 13	E-mail string re Presentation	
8		Materials: Due Feb 1, Bates	
9		PPLP004349855 to 0043498900	122
10	No. 14	E-mail string re Presentation	
11		materials: Due Feb 1, Bates	
12		PPLP004353080 to 004353084	124
13	No. 15	E-mail string re SOP Presentation	
14		Deadline, Bates PPLP004084596 to	
15		004084599	129
16	No. 16	E-mail string re Confirmation for	
17		SOP Lecture and Workshops, Bates	
18		PPLP004351948 to 004351951	129
19	No. 17	Brochure entitled "Safe Opioid	
20		Prescribing"	134
21	No. 18	Letter to Martin Grabois from the	
22		United States Senate, dated	
23		May 8, 2012	140
24			

1 E X H I B I T S (Continued)

2 (Attached to transcript)

3 AAPM-TATUM DEPOSITION EXHIBITS PAGE

4 No. 19 HSGAC Brochure entitled "Fueling
5 an Epidemic," Report Two, Exposing
6 the Financial Ties Between Opioid
7 Manufacturers and Third Party

8 Advocacy Groups 143

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

1 P R O C E E D I N G S

2 -----

3 THE VIDEOGRAPHER: We are now on the
4 record. My name is Daniel Holmstock. I'm the
5 videographer for Golkow Litigation Services.
6 Today's date is December 11th, 2018, and the time
7 on the video screen is 9:27 a.m.

8 This video deposition is being held at
9 the law offices of Motley Rice, LLC, at 401 9th
10 Street, Northwest, in Washington, D.C., in the
11 matter of In Re: National Prescription Opiate
12 Litigation. It's pending before the United States
13 District Court for the Northern District of Ohio,
14 Eastern Division.

15 The deponent is Elizabeth Tatum.

16 Counsel will be noted on the
17 stenographic record for appearances.

18 The court reporter is Leslie A. Todd,
19 who will now administer the oath.

20 ELIZABETH T. TATUM,

21 and having been first duly sworn,

22 was examined and testified as follows:

23 DIRECT EXAMINATION

24 BY MS. BAISCH:

1 Q Good morning. My name is Krista Baisch.
2 I am one of the attorneys that represents the
3 plaintiffs in this matter. I just introduced
4 myself to you off the record.

5 May I call you Elizabeth today?

6 A Yes.

7 Q All right. Can you please state your
8 full name?

9 A Yes. Elizabeth Therese Tatum.

10 Q And have you ever been deposed before?

11 A No.

12 Q Do you understand that you were just put
13 under oath?

14 A Yes.

15 Q Are you taking any medication or is
16 there any reason why your memory may be impaired?

17 A No.

18 Q Is there any other reason --

19 A Actually, excuse me, I am taking one
20 type of medication, but --

21 Q Would it interfere with your -- your
22 memory?

23 A No.

24 Q Is there any reason that your ability to

1 answer my questions fully and truthfully today
2 would be a problem?

3 A No.

4 Q All right. I'm going to ask you a
5 series of questions. If you provide an answer,
6 then I'm going to assume you understood my
7 question. Okay?

8 A Okay.

9 Q If at any time you do not understand my
10 question, you'll need to tell me. Okay?

11 A Okay.

12 Q And if at any time you need a break,
13 you'll need to tell me. Okay?

14 A Okay.

15 Q Do you recall when you were first
16 contacted about this case?

17 A Yes.

18 Q When was that?

19 A It was this summer.

20 Q The summer of 2018?

21 A Yes.

22 Q Do you recall who contacted you?

23 A Yes.

24 Q Who was that?

1 A Desiree Torres with Griffin Strategies.

2 Q And what did Desiree tell you?

3 A She told me she was an investigator
4 serving with a law firm that was part of a -- some
5 sort of lawsuit.

6 Q Did she confirm with you that you were a
7 former employee of AAPM?

8 A She did.

9 Q And what is AAPM?

10 A The American Academy of Pain Medicine.

11 Q Did she confirm with you your prior
12 position with AAPM?

13 A She did.

14 Q Did she ask you whether you were
15 represented by counsel at that time?

16 A No, she did not.

17 Q Were you represented by counsel at that
18 time?

19 A No.

20 Q Did you agree to be interviewed by her?

21 A Yes.

22 Q And were you interviewed by her?

23 A Yes.

24 Q Were you asked if you would submit a

1 written statement called a declaration consistent
2 with the facts you shared during your interview?

3 A She did ask me. Not at the beginning.

4 Q Did you ever sign such a statement?

5 A No.

6 Q At what point did you retain legal
7 counsel?

8 MR. ENGLAND: Objection.

9 You can answer.

10 THE WITNESS: I don't remember the exact
11 date.

12 BY MS. BAISCH:

13 Q Was it sometime in the summer of 2018?

14 A Yes.

15 Q Was it before you were asked to submit a
16 written statement?

17 A No.

18 Q Is the legal counsel you retained the
19 same legal counsel representing you here today?

20 A Yes.

21 Q Is any corporation or company paying for
22 your legal counsel?

23 A No.

24 Q After you retained legal counsel, did

1 the investigator contact you again?

2 A Yes.

3 Q Did you refer the investigator to your
4 legal counsel?

5 A Yes.

6 Q Were you ever contacted by the
7 investigator after that?

8 A No, not that I recall.

9 Q Were you ever contacted by plaintiffs'
10 counsel prior to your retaining legal counsel?

11 A No.

12 Q Have you ever been contacted by legal
13 counsel?

14 A By legal counsel --

15 Q I'm sorry, for -- legal counsel for the
16 plaintiffs.

17 A No.

18 (A discussion was held off the record.)

19 (Tatum Exhibit No. 1 was marked
20 for identification.)

21 BY MS. BAISCH:

22 Q Elizabeth, I've placed in front of you a
23 document that we've marked today as Tatum document
24 number -- Exhibit No. 1. Do you recognize this

1 document?

2 A I do.

3 Q Did you -- and this is a subpoena to
4 testify at a deposition in a civil action; is that
5 correct?

6 A Yes, it is.

7 Q And did you receive this document?

8 A Yes.

9 Q And do you agree that you are appearing
10 today pursuant to that subpoena?

11 A Yes.

12 Q And do you understand that we are here
13 today to discuss your knowledge about AAPM as it
14 relates to the litigation that was put on the
15 record earlier?

16 A Yes.

17 Q And do you understand that we are here
18 to discuss your recollection consistent with
19 information that you previously provided to the
20 investigator?

21 MS. VICARI: Objection to form.

22 THE WITNESS: Can you restate the
23 question?

24 MS. BAISCH: Yeah. Can you read it

1 back.

2 (Whereupon, the requested record
3 was read.)

4 THE WITNESS: Yes.

5 BY MS. BAISCH:

6 Q Did you meet with counsel to prepare for
7 today's deposition?

8 A We had a couple of discussions, yes.

9 Q Do you recall how many?

10 A No.

11 Q More than two?

12 A Yes.

13 Q More than five?

14 A No.

15 Q When did you meet with your attorney?

16 A We've had conversations over the phone
17 on a few occasions.

18 Q Did you review any documents to prepare
19 for this deposition?

20 A No.

21 Q Do you have any documents from the time
22 frame wherein you were employed at AAPM?

23 A I --

24 Q Related to AAPM to be clear.

1 A I -- I -- I may. I'm not sure.

2 Q Have you looked for them?

3 A No.

4 Q Have you talked to anyone other than
5 your lawyer to prepare for today's deposition?

6 A No.

7 Q Did you go to college?

8 A Yes.

9 Q When?

10 A 2004 to 2008.

11 Q Where?

12 A Taylor University in Upland, Indiana.

13 Q Did you earn a degree?

14 A Yes, I did.

15 Q What was your degree?

16 A Bachelor of Science, English education.

17 Q What did you do after graduating from
18 college in 2008?

19 A Yes, I graduated in 2008. And for six
20 or nine months after graduation, I worked a
21 variety of part-time jobs, including nannying,
22 working at a library, making calls for the Chicago
23 Symphony Orchestra.

24 And following that, I took a position

1 with Association Management Center, and the
2 American Academy of Pain Medicine was the client I
3 served.

4 Q Okay. Where do you work today?

5 A I work at Deloitte Consulting.

6 Q And what is your position at Deloitte
7 Consulting?

8 A I'm a senior consultant in the
9 government and public services practice.

10 Q Do you recall when you started your
11 employment with the Association Management Center?

12 A I started as a temp to hire in -- let's
13 see -- in 2008. Then I don't remember when I
14 became a full employee. Maybe three -- three or
15 six months after.

16 Q Were you immediately assigned to the
17 American Academy of Pain Medicine?

18 A Yes.

19 Q So from the time that you started --
20 from the time that you started with the
21 Association Management Center --

22 MR. ENGLAND: I'm sorry.

23 MS. BAISCH: That's all right.

24 MR. ENGLAND: Excuse me. I'm so sorry.

1 It may be the room. I don't know. It just comes
2 on.

3 MS. BAISCH: No problem.

4 BY MS. BAISCH:

5 Q I'm just going to start that over.

6 So from the time that you started with
7 the Association Management Center, you started
8 working with the American Academy of Pain
9 Medicine?

10 A Yes.

11 Q And what was your position at AAPM?

12 A My first position was -- the title was
13 account administrator.

14 Q How long were you account administrator?

15 MS. BAISCH: Do you -- why don't we take
16 a break? I'm sorry.

17 THE VIDEOGRAPHER: The time is 9:37 a.m.
18 We're going off the record.

19 (Pause in the proceedings.)

20 THE VIDEOGRAPHER: The time is 9:38 a.m.
21 We're back on the record.

22 BY MS. BAISCH:

23 Q All right, Elizabeth, how long were you
24 the account administrator at AAPM?

1 A I don't recall the exact dates.

2 Q Do you recall what your next position
3 was at AAPM?

4 A Yes.

5 Q What was that?

6 A The title was special projects
7 coordinator.

8 Q Do you recall how long you were special
9 projects coordinator?

10 A Again, I don't remember the exact dates.
11 I would need to look at my resume.

12 Q Did you hold any positions other than
13 account administrator and special project
14 coordinator while you were at AAPM?

15 A Yes.

16 Q Can you tell me what your job duties
17 were as the account administrator -- oh, I'm
18 sorry, did you say "yes"?

19 A Yes.

20 Q Okay. What other positions?

21 A The last position was education
22 coordinator.

23 Q Can you tell me what your job duties
24 were as an account administrator?

1 A I served as an assistant to the
2 executive director. I scheduled meetings, I took
3 notes, I drafted letters, memorandum, and provided
4 general administrative support.

5 Q And who was the executive director
6 during that time?

7 A Philip Saigh.

8 Q What were your job duties as a special
9 project coordinator?

10 A They were essentially the same as the
11 previous position. It was providing
12 administrative assistance.

13 Q Administrative assistance to who?

14 A To the executive director. Also to the
15 director of operations.

16 Q Anybody else?

17 A No.

18 Q Who was the director of operations
19 during that time?

20 A Sarah Bilissis.

21 Q Do you know how to spell that, by any
22 chance?

23 A B-I-L-I-S-S-I-S. She may have changed
24 her last name, I'm not sure, but that's what it

1 was at that time.

2 Q Other than Philip Saigh and Sarah
3 Bilissis, did you report to anyone else during
4 your employment at AAPM?

5 A Yes.

6 Q Who else?

7 A Towards the end I was reporting to Susie
8 Flynn.

9 Q What was Susie's title?

10 A Director of education.

11 Q Was that when you were education
12 coordinator?

13 A Yes.

14 Q What were your job duties as education
15 coordinator?

16 A I provided administrative support to
17 Susie. So I helped prepare documents, I helped
18 with logistical arrangements for educational
19 conferences, and I also helped prepare
20 applications for educational grants.

21 Q Other than Susie Flynn, Sarah Bilissis
22 and Philip Saigh, did you report to anyone else
23 during your time at AAPM?

24 A No.

1 Q You started -- you said you started with
2 AAPM in 2008. When did you leave AAPM?

3 A 2012.

4 Q Do you recall when in 2012?

5 A Yes. Summer of 2012.

6 Q Late summer or early summer?

7 A Late summer.

8 Q So August of 2012?

9 A Yes. That's -- yes.

10 Q Are you familiar with the manufacturers
11 of opioid pharmaceuticals?

12 A I'm not --

13 MS. VICARI: Objection to form.

14 THE WITNESS: Yeah, I'm not sure I
15 understand the question, when you say am I
16 familiar.

17 BY MS. BAISCH:

18 Q Mm-hmm.

19 A What -- what do you mean by "familiar"?

20 Q If I say "manufacturer of opioids" --

21 A Mm-hmm.

22 Q -- do you know who I'm referring to?

23 Let me state it this way: I just want
24 to get on the right terminology with you.

1 A Sure.

2 Q So we're going to start talking about
3 during the time frame that you were at AAPM, the
4 entities that you worked with.

5 A I see.

6 MS. VICARI: Objection to form.

7 BY MS. BAISCH:

8 Q So what industry -- what industry did
9 you work with when you were at AAPM?

10 MS. VICARI: Objection to form.

11 THE WITNESS: The -- so I worked for the
12 American Academy of Pain Medicine, and it was -- I
13 worked for the association, a professional
14 association of physicians.

15 BY MS. BAISCH:

16 Q Did you have any contact with outside
17 companies during that time frame?

18 A Yes.

19 Q Were they pharmaceutical companies?

20 A Some. Yes.

21 Q What other types of companies?

22 A I don't recall. I don't recall, but I
23 think there was more than pharmaceutical
24 companies.

1 Q Do you know whether the pharmaceutical
2 companies that you interacted with, whether or not
3 they manufactured opioids?

4 A Yes.

5 Q So if I say -- if I say "opioid
6 manufacturer," do you understand what that means?

7 A Yes, I do.

8 Q Okay. Have you ever received any
9 compensation directly from an opioid manufacturer?

10 A No.

11 Q Have you ever received any compensation
12 directly from a distributor of opioid
13 manufacturers?

14 A No.

15 Q Have you ever received any compensation
16 directly from a pharmacy that distributes opioids?

17 A No.

18 Q All right. What is the Association
19 Management Center?

20 A It is a privately held company that
21 provides management services, full-service
22 management services to professional associations.

23 Q Does it manage healthcare societies?

24 A Yes.

1 Q Does it manage any type of societies or
2 associations other than healthcare?

3 A Yes.

4 Q Do you know how many healthcare
5 societies it managed?

6 A No.

7 Q Do you know of any healthcare societies
8 it managed other than the American Academy of Pain
9 Medicine?

10 A Yes.

11 Q Can you tell me what they are?

12 A There was the American Academy of
13 Hospice and Palliative Medicine. The American
14 Pain Society. There were plenty of others. It's
15 been a long time. I don't remember.

16 Q Do you know when the Association
17 Management Center was first started?

18 A No.

19 Q Do -- what types of administrative
20 services did AMC provide?

21 A They provided, again, full-service
22 management services. So the entire staff for a
23 professional association would -- would be
24 provided by AMC.

1 Q Even the executive director?

2 A I don't know what those arrangements
3 were, but, yes -- yes, that person was an employee
4 of AMC as well.

5 Q So all of the -- all of the employees of
6 AAPM were employees of AMC?

7 A Yes.

8 MS. VICARI: Counsel, just so the record
9 is clear, we're going to -- AMC is going to be the
10 Association Management Center, is that the acronym
11 used?

12 MS. BAISCH: Yes, Association Management
13 Center will be AMC.

14 BY MS. BAISCH:

15 Q Are you familiar with Partners Against
16 Pain?

17 A No.

18 Q Do you know when the American Academy of
19 Pain Medicine was first started?

20 A No.

21 Q And we are going to refer to American
22 Academy of Pain Medicine as AAPM. Are you okay
23 with that?

24 A Yes.

1 Q During the time frame that you worked
2 with AAPM, how many staff members were at AAPM?

3 A I don't recall the exact number.

4 Q Was it more than ten?

5 A No.

6 Q Was it more than five?

7 A Yes.

8 Q Can you tell me what type of staff
9 members would have worked at AAPM?

10 A Yes. There was an executive director,
11 marketing, operations, and education.

12 Q Was Phil Saigh the executive director
13 the entire time that you were at AAPM?

14 A Yes.

15 Q And was Susie Flynn the director of
16 education the entire time you were at AAPM?

17 A Yes.

18 Q And was Sarah Bilissis the director of
19 operations the entire time you were at AAPM?

20 A Yes.

21 Q Who was the director of marketing?

22 A I don't recall her last name.

23 Q Do you recall her first name?

24 A Sue.

1 Q Did anybody work with the executive
2 director, under the executive director other than
3 the administrative assistant -- account
4 administrator? Sorry.

5 A Yes.

6 Q What other positions worked with the
7 executive director?

8 A Do you mean direct reports?

9 Q Yes.

10 A The director of operations, director of
11 education, and director of marketing.

12 Q Okay. So all -- all three of the other
13 directors, director of marketing, director of
14 operations and director of education, all three of
15 them reported to the executive director?

16 A Yes.

17 Q Was there a different director for sales
18 or is that marketing?

19 A There was a different director for
20 sales, yes.

21 Q And who did the director of sales report
22 to?

23 A I don't recall. I don't know what that
24 arrangement was.

1 Q Do you recall who the director of sales
2 was during the time frame that you were at AAPM?

3 A Yes.

4 Q Who was that?

5 A Kathy Checea.

6 I can try to spell her last name.

7 Q Please do so.

8 A C-H-E-C-E-A.

9 Q Thank you.

10 Who else would have worked with the
11 director of education? What other positions, I
12 should say?

13 A There was another education coordinator.

14 Q And who was that?

15 A Her first name -- her first name was
16 Mary.

17 Q Was it Mary O'Keefe?

18 A Yes.

19 Q O-K-E-E-F-E?

20 A Mm-hmm.

21 Q Is that a "yes"?

22 A Yes.

23 Q Was there anyone else who worked with
24 the director of marketing?

1 A Yes.

2 Q Who?

3 A Her name was Pola Henderson.

4 Q And what was Pola's position?

5 A I don't remember the title.

6 Q How do you spell Pola?

7 A P-O-L-A.

8 Q And did anybody else work with the
9 director of sales?

10 A Yes.

11 Q Who?

12 A She had a number of direct reports.

13 I -- I don't know their -- I don't know the name
14 of the -- all of those team members.

15 Q Was it more than five?

16 A I -- I don't -- I honestly don't know.

17 Q Do you know what the -- what the team
18 members for the director of sales, what their job
19 responsibilities were?

20 A Not the full scope of their job
21 responsibilities, no.

22 Q What is the scope as you understand it?

23 A So I -- I know they helped with our --
24 the exhibit booths, selling exhibit space at the

1 annual conference. And handling those
2 relationships, so coordinating with folks,
3 recruiting them to hold exhibit space. Beyond
4 that, I -- I don't know.

5 Q Did anybody work -- did anybody work
6 under the director of operations?

7 A Yes.

8 Q Do you recall what that position was?

9 A I don't remember the title. Operations
10 assistant coordinator. Something like that.

11 Q Do you recall who it was?

12 A Yes.

13 Q Who was that?

14 A Her first name was Carolyn. Again, I
15 don't remember her last name.

16 Q Okay. So we have just -- any other
17 positions that we haven't covered that you can
18 recall during the time frame that you were at
19 AAPM?

20 A There was a communications or a graphic
21 design staff member, but they weren't with -- they
22 were not a full-time employee. So helped us with
23 preparing materials and layout, that kind of
24 thing.

1 Q All right. So we had -- during the time
2 frame that you were at AAPE -- AAPM, Phil Saigh
3 was the executive director, and then under him, we
4 had the director of marketing who was named Sue;
5 is that correct?

6 A Yes.

7 Q The director of operations, whose name
8 was Sarah Bilissis; is that correct?

9 A Yes.

10 Q And then the director of education, who
11 was Susie Flynn; is that correct?

12 A Yes.

13 Q And then Mary O'Keefe worked with Susie
14 Flynn; is that correct?

15 A Yes.

16 Q And Carolyn worked with Sarah Bilissis;
17 is that correct?

18 A Yes.

19 Q And then there -- did anybody work with
20 Sue on marketing?

21 A Yes. Pola Henderson.

22 Q Oh, yes. Okay.

23 Did all of these people work at the
24 Glenview office in Illinois during the time frame

1 that you were at AAPM?

2 A Yes.

3 Q Was the director of sales in that office
4 too?

5 A Yes.

6 Q All right. What did the AAPM do?

7 A It was a professional association for
8 pain medicine physicians. So they organized an
9 annual conference, provided continuing medical
10 education. Provided a forum, I suppose, for
11 physicians to interact and discuss their
12 profession.

13 Q So the AAPM would host an annual
14 conference every year?

15 A Yes.

16 Q And the AAPM would host CMEs?

17 A Yes.

18 Q Would the AAPM host forums for
19 physicians?

20 A They organized them, yes.

21 Q What do you mean by that? Is that
22 something different -- let me ask it this way: Is
23 that something different from the annual
24 conference and the CMEs?

1 A No.

2 Q So were there any types of events that
3 the AAPM would host other than the annual
4 conference and CMEs?

5 A No.

6 Q Did the AAPM prepare publications?

7 A Yes.

8 Q What kind of publications?

9 A A medical journal.

10 Q Anything else?

11 A They -- I -- I don't remember exactly.
12 I know that they -- there was a website, there was
13 material on the website. They would publish press
14 releases or statements. I don't recall anything
15 beyond that.

16 Q And who -- what type of people would be
17 members of the AAPM?

18 MS. VICARI: Objection to form.

19 THE WITNESS: Physicians. And there
20 were also affiliate memberships for healthcare
21 providers who were not physicians.

22 BY MS. BAISCH:

23 Q What about researchers?

24 A I'm not sure if that was a class that

1 was permitted.

2 Q Anything other than physicians and
3 affiliated members?

4 A No.

5 Q How are corporations involved with the
6 AAPM?

7 MS. VICARI: Object to the form.

8 THE WITNESS: Companies provided --
9 provided sponsorship for events, and companies
10 also purchased booth space in the exhibit hall.

11 BY MS. BAISCH:

12 Q Anything else?

13 A No.

14 Q Can you tell me during the time frame
15 that you were at AAPM who you would have
16 considered the person the most knowledgeable about
17 AAPM's interactions with pharmaceutical companies?

18 A The executive director.

19 Q Phil Saigh?

20 A Yes.

21 Q Are you familiar with the Corporate
22 Relations Council of AAPM?

23 A Yes.

24 Q What is the Corporate Relations Council?

1 A That was a gathering of companies who
2 provided sponsorship and typically would hold one
3 meeting at the annual conference.

4 Q You said it was a council of companies?

5 A Yes.

6 Q What kind of companies?

7 A Pharmaceutical companies and other
8 companies providing healthcare services related to
9 pain management.

10 Q How many companies were on the Corporate
11 Relations Council during the time frame that you
12 worked at AAPM?

13 A I don't recall.

14 Q Was it more than ten?

15 A I'm not -- I'm not sure.

16 Q Do you know if it was more than 20?

17 A No, I don't think so.

18 Q Do you know was it -- would you say it
19 was somewhere around ten?

20 A Sure. Yes.

21 Q Do you know if Purdue was on the
22 Corporate Relations Council?

23 A No, I don't recall.

24 Q Do you know whether Endo was on the

1 corporation relations council?

2 A I don't -- I don't recall.

3 Q Do you know whether Teva was on the
4 Corporate Relations Council?

5 A I -- I don't recall that either.

6 Q Do you recall whether Cephalon was on
7 the Corporate Relations Council?

8 A I -- I don't recall.

9 Q Do you know whether Mallinckrodt was on
10 the Corporate Relations Council?

11 A I don't know.

12 Q Do you know whether Pfizer was on the
13 Corporate Relations Council?

14 A I don't know.

15 Q Do you know whether Janssen was on the
16 Corporate Relations Council?

17 A I don't know.

18 Q Do you know whether Johnson & Johnson
19 was on the Corporate Relations Council?

20 A I don't know.

21 Q Do you know whether Allergan was on the
22 Corporate Relations Council?

23 A I don't know.

24 Q Do you know whether Actavis was on the

1 Corporate Relations Council?

2 A I don't know.

3 Q Do you know whether Covidien was on the
4 Corporate Relations Council?

5 A I don't know.

6 Q Do you know whether Insys was on the
7 Corporate Relations Council?

8 A I'm not sure.

9 Q Do you know how corporations got a seat
10 on the council?

11 A I don't remember the particular details.
12 I would need materials. It's been over six years.

13 Q What kind of materials would you need?

14 A Materials the organization prepared
15 about the -- what the Corporate Relations Council
16 is and how to belong to it.

17 Q Did corporations pay money to get a seat
18 on the council?

19 MS. VICARI: Object to form.

20 THE WITNESS: A level of sponsorship was
21 required, I -- I believe.

22 BY MS. BAISCH:

23 Q Do you know, were there different types
24 of levels of sponsorship?

1 A Yes.

2 Q And were there benefits associated with
3 each level of sponsorship?

4 A Yes.

5 Q Can you give me an example of a benefit
6 that would be associated with a level of
7 sponsorship?

8 A An invitation to the Corporate Relations
9 Council meeting.

10 Q Were all companies that donated money to
11 the AAPM to be on the Corporate Relations Council
12 invited to the Corporate Relations Council
13 meeting?

14 MS. VICARI: Objection. Form.

15 THE WITNESS: Could you say that again?

16 MS. BAISCH: Yes.

17 Could you read that back.

18 (Whereupon, the requested record
19 was read.)

20 BY MS. BAISCH:

21 Q I'm sorry, I'll reask that question.

22 A Yeah. Okay.

23 Q Okay. Were all companies that paid
24 money for the sponsorship for the Corporate

1 Relations Council invited to the Corporate
2 Relations Council meeting?

3 MS. VICARI: Objection to form.

4 THE WITNESS: I don't remember the
5 levels of sponsorship and who received which
6 benefit.

7 BY MS. BAISCH:

8 Q Okay. So you don't know if there was --
9 if there would have been a, like, low level of
10 sponsorship that would have not included a meeting
11 invite?

12 A Correct.

13 Q Can you give an example of any other
14 types of benefits that a member of the Corporate
15 Relations Council would receive when they paid
16 money to the AAPM?

17 MS. VICARI: Objection to form.

18 THE WITNESS: I -- I don't recall. I
19 know the Corporate Relations Council meeting was a
20 benefit. I -- anything else would just be me
21 speculating about what it was.

22 BY MS. BAISCH:

23 Q Did you ever attend a Corporate
24 Relations Council meeting?

1 A Yes.

2 Q Do you recall how many times?

3 A Two or three times.

4 Q Other than the companies that pay money
5 to the AAPM to be on the Corporate Relations
6 Council, what other type of people would be at the
7 Corporate Relations Council meeting?

8 MS. VICARI: Objection. Form.

9 THE WITNESS: Other -- other attendees.

10 BY MS. BAISCH:

11 Q What do you mean by that?

12 A Well, you're -- you're asking -- I'm not
13 sure I understand your question. Can you reask
14 it?

15 Q Is the Corporate Relations Council
16 meeting a meeting between the Corporate Relations
17 Council and the AAPM board?

18 A Yes.

19 Q Is there anybody other than the AAPM
20 board and the companies that pay money to be at
21 the Corporate Relations Council meeting?

22 A Yes.

23 MS. VICARI: Objection to form.

24 BY MS. BAISCH:

1 Q Who?

2 A Staff members.

3 Q What kind of staff members?

4 A Members of the AAPM staff.

5 Q All staff members?

6 A No, I don't think so.

7 Q Would the executive director attend?

8 A Yes.

9 Q Would the director of operations attend?

10 A Yes.

11 Q Would the director of marketing attend?

12 A Yeah -- yes. There -- there wasn't a --
13 a set list. I don't know how -- I don't know what
14 the expectation was for staff members to attend.
15 I needed to be there, but I don't know who had --
16 who else was required to be there.

17 Q So you needed to be there, the AAPM
18 board needed to be there, and the companies that
19 paid money to be on the Corporate Relations
20 Council needed to be there.

21 MS. VICARI: Objection to form.

22 THE WITNESS: I don't know what you mean
23 by -- by "needed to be there." I mean, were they
24 required to be there? Is that what you're asking?

1 BY MS. BAISCH:

2 Q Well, you used the word "needed." I was
3 just using your word.

4 A Well, as --

5 Q What do you mean by "needed to be
6 there"?

7 A Right, so I needed to be there because I
8 was a paid staff member and I provided -- I put up
9 tent cards, I printed out board materials. I was
10 there to help the meeting to go smoothly.

11 Q And what happened at the meetings
12 between the Corporate Relations Council and the
13 AAPM board?

14 MS. VICARI: Objection. Form, vague.

15 THE WITNESS: There was an agenda with
16 different discussion items of interest. I don't
17 remember what those agenda items were.

18 BY MS. BAISCH:

19 Q What do you mean by discussion items of
20 interest?

21 A I -- hmm. There may have been
22 discussion about industry support. I really
23 don't -- I really don't remember what -- I really
24 don't remember what the discussion items were.

1 Q And would it -- would the meeting for
2 the Corporate Relations Council and the AAPM
3 board, would that be open to members at large?

4 A No.

5 Q So it was just the companies that paid
6 money to be on the Corporate Relations Council,
7 the AA -- AAPM board, and then the staff members
8 from the AAPM that -- that were attending the
9 meeting?

10 A Correct.

11 MS. VICARI: Objection to form.

12 BY MS. BAISCH:

13 Q And do you know what type of
14 representatives from the companies that paid money
15 to be on the Corporate Relations Council, like
16 what type of people from those companies would
17 attend those meetings?

18 MS. VICARI: Objection to form.

19 THE WITNESS: I believe it was up to the
20 companies to decide who -- who to send.

21 BY MS. BAISCH:

22 Q And do you know how many from any one
23 particular company could attend the meeting?

24 A Somewhere between one and three people.

1 MR. ENGLAND: Counsel, let me stop you.
2 Can we take -- I don't mean to stop so early, but
3 can I just take five or so --

4 MS. BAISCH: Yes, of course.

5 THE VIDEOGRAPHER: The time is 10:10
6 a.m. We're going off the record.

7 (Recess.)

8 THE VIDEOGRAPHER: The time is
9 10:21 a.m., and we're back on the record.

10 BY MS. BAISCH:

11 Q All right. Elizabeth, we were talking
12 about the Corporate Relations Council. Earlier I
13 went through some companies, and you didn't recall
14 whether or not they were on the Corporate
15 Relations Council; is that correct?

16 A That's correct.

17 Q Do you recall now the name of any
18 companies that were on the Corporate Relations
19 Council?

20 A No.

21 Q Do you recall whether the companies that
22 were on the Corporate Relations Council were --
23 were manufacturers of opioid pharmaceuticals?

24 A Yes.

1 Q Yes, they were?

2 A Yes.

3 Q Other than having access to the AA --
4 the AAPM board during the Corporate Relations
5 Council meeting, can you recall now whether there
6 were any other benefits of being on the Corporate
7 Relations Council?

8 MS. VICARI: Objection to form.

9 THE WITNESS: There were other benefits.
10 I don't recall what they were.

11 BY MS. BAISCH:

12 Q And the benefits corresponded to the
13 amount of money that the company paid; is that
14 correct?

15 MS. VICARI: Objection to form.

16 THE WITNESS: That's correct, yes.

17 BY MS. BAISCH:

18 Q Do you know how long the Corporate
19 Relations Council meeting would last?

20 MS. VICARI: Objection. Form.

21 THE WITNESS: One hour.

22 BY MS. BAISCH:

23 Q Who prepared the agenda for the
24 Corporate Relations Council meeting?

1 MS. VICARI: Objection to form.

2 THE WITNESS: I believe the AAPM staff
3 drafted the agenda.

4 BY MS. BAISCH:

5 Q Did -- did the members of the Corporate
6 Relations Council contribute to the agenda?

7 MS. VICARI: Objection to form.

8 THE WITNESS: I don't recall.

9 BY MS. BAISCH:

10 Q Do you recall discussions related to a
11 Pain Medicine Foundation?

12 A Yes.

13 Q What was the Pain Medicine Foundation?

14 A It was a concept that the board
15 discussed a foundation to fund advocacy for their
16 profession and medical education.

17 Q Did the AAPM board discuss the Pain
18 Medicine Foundation with the Corporate Relations
19 Council?

20 MS. VICARI: Objection to form.

21 THE WITNESS: I don't remember.

22 BY MS. BAISCH:

23 Q Do you know how the pain -- do you know
24 whether the Pain Medicine Foundation was started?

1 A Yes. I believe it was.

2 Q Do you know how the Pain Medicine
3 Foundation was funded?

4 A No.

5 Q Who would know the answer to -- and
6 during the time frame that you were at the AAPM,
7 who would you ask for the answer to how was the
8 Pain Medicine Foundation funded?

9 A Phil Saigh.

10 Q Can you describe generally what your
11 interactions were with the AAPM board?

12 A Yes. I scheduled meetings. I would
13 draft letters or memos that a board member would
14 sign. I handed out printed material at board
15 meetings. I also took notes during their meetings
16 and I took notes during phone calls.

17 Q How often did the board meet?

18 A The full board met twice a year.

19 Q Were there subcommittees to the board?

20 A There was an executive committee on the
21 board.

22 Q Any subcommittees other than the
23 executive committee?

24 A Not that I remember.

1 Q Was there a conflict of interest
2 committee?

3 A There was a conflict of interest
4 committee. It was not part of the board.

5 Q What do you mean by that?

6 A The board of directors was defined by
7 the organization's bylaws. So the conflict of
8 interest committee members were different than the
9 board.

10 Q Were there -- during your -- the time
11 that you were at AAPM, do you recall any persons
12 that were both a member of the conflict of
13 interest committee and the board of directors?

14 A Yes.

15 Q So there was some overlap.

16 A Yes.

17 Q All right. How many persons were on the
18 board of directors for AAPM?

19 A I don't --

20 MS. VICARI: Objection. Vague as to
21 time.

22 BY MS. BAISCH:

23 Q During the time -- during the time frame
24 that you were at AAPM, how many persons were on

1 the board of directors for AAPM?

2 A I don't know the exact number.

3 Q More than 10?

4 A Yes.

5 Q Less than 20?

6 A Yes.

7 Q Somewhere around 15?

8 A Yes.

9 Q Did you have to be a member of AAPM to
10 have a position on the board of directors?

11 A Yes.

12 Q Were any -- I'm sorry. Do you recall
13 the names of any persons who were on the board of
14 directors during the time frame that you were at
15 AAPM?

16 A Yes.

17 Q What names do you recall?

18 A Eddie Fraifeld.

19 Q Can you spell that?

20 A The -- the last name?

21 Q Yes.

22 A F-R-A-I-F-E-L-D.

23 Zahid Bajwa, Z-A-H-I-D, B-A-J-W-A.

24 Rollin Gallagher. Donna Bloodworth. Philipp

1 Lippe.

2 Q How do you spell Lippe?

3 A Lippe, L-I-P-P-E.

4 Perry Fine. Lynn Webster. Scott

5 Fishman. Jerome Schofferman.

6 Q Did you say Jerome?

7 A Jerome.

8 Q And the last name was?

9 A Schofferman.

10 That's -- that's all I remember.

11 Q Do you recall whether David Haddox was

12 on the board of the AAPM during the time frame

13 that you were employed at AAPM?

14 A Yes, he was on the board.

15 Q Do you recall the names of any other

16 persons who were on the board of directors at AAPM

17 during the time frame that you were at AAPM?

18 A No.

19 Q Can you tell me how a member of the AAPM

20 got a position on the board of directors?

21 MS. VICARI: Objection to form.

22 THE WITNESS: There was a nominating

23 committee, and then there was a vote by the

24 members.

1 BY MS. BAISCH:

2 Q How often did that take place?

3 A Once a year.

4 Q You mentioned an executive committee.

5 Do you recall how many persons were on the
6 executive committee during the time frame that you
7 were at AAPM?

8 A Somewhere between five and eight.

9 Q During -- of the persons that you have
10 identified as being on the board of directors, do
11 you recall which of those persons were also on the
12 executive committee?

13 MS. VICARI: Objection to form.

14 THE WITNESS: Yes.

15 BY MS. BAISCH:

16 Q Can you tell me who was on the executive
17 committee during the time frame that you worked
18 for AAPM?

19 A I don't -- the executive committee would
20 change. I don't remember who belonged to it when.

21 Q How did the executive committee differ
22 from the -- the board of directors?

23 A The executive committee met more
24 regularly.

1 Q More than twice per year.

2 A Yes.

3 Q Do you know how many times the executive
4 committee would meet per year?

5 MS. VICARI: Objection to form.

6 THE WITNESS: They met once per month.

7 BY MS. BAISCH:

8 Q So approximately 12 times per year?

9 A It -- it may have been once a month or
10 every other month. I don't remember which.

11 Q Do you recall whether Eddie Fraifeld was
12 on the --

13 A Fraifeld.

14 Q -- executive commit- -- committee?

15 A Yes.

16 Q Do you recall whether Zahid Bajwa was on
17 the executive committee?

18 A Yes.

19 Q Yes, he was?

20 A Yes, he was.

21 Q Do you recall whether Rollin Gallagher
22 was on the executive committee?

23 A Yes, he was.

24 Q Do you recall whether Donna Bloodworth

1 was on the executive committee?

2 A No, I'm not sure. I can't remember.

3 Q Do you recall whether Philipp Lippe was
4 on the executive committee?

5 A I don't remember.

6 Q Do you recall whether Perry Fine was on
7 the executive committee?

8 A Yes, he was.

9 Q Do you recall whether Lynn Webster was
10 on the executive committee?

11 A Yes, he was.

12 Q Do you recall whether Scott Fishman was
13 on the executive committee?

14 A No.

15 Q Do you recall whether Jerome Schofferman
16 was on the executive committee?

17 A No.

18 Q Do you recall whether David Haddox was
19 on the executive committee?

20 A No.

21 Q Are there any other persons that you can
22 recall right now that would have been on the
23 executive committee during any of the time frame
24 that you worked at AAPM?

1 A No.

2 Q Do you recall how many persons were on
3 the conflict of interest committee?

4 MS. VICARI: Objection. Form.

5 THE WITNESS: Somewhere between five and
6 eight.

7 BY MS. BAISCH:

8 Q Do you recall the names of any of the
9 persons on the conflict of interest committee
10 during the time frame that you worked at AAPM?

11 A Yes. Jerome Schofferman.

12 Q Do you recall anybody other than Jerome
13 Schofferman?

14 A No.

15 Q And what did the conflict of interest
16 committee do?

17 A They met to discuss a revision of the
18 conflict of interest form.

19 Q Anything else?

20 A There were general discussions about
21 support from companies.

22 Q Anything else?

23 A No.

24 Q You attended the AAPM board of director

1 meetings?

2 A Yes.

3 Q What types of things would be discussed
4 at the board of director meetings?

5 MS. VICARI: Objection. Form.

6 THE WITNESS: They discussed the
7 organization's budget. They would discuss the
8 annual meeting. They would discuss the American
9 Board of Pain Medicine. They would discuss an
10 interest in making pain medicine a specialty. And
11 really any other business of the association.

12 BY MS. BAISCH:

13 Q Would the board of directors be the
14 entity that would determine what AAPM would focus
15 on?

16 MS. VICARI: Object to form.

17 THE WITNESS: Yes.

18 BY MS. BAISCH:

19 Q Would the board of directors determine
20 what types of issues would be discussed at the
21 annual AAPM meeting?

22 A Yes.

23 MS. VICARI: Objection to form.

24 BY MS. BAISCH:

1 Q Would the board of directors determine
2 what AAPM's strategy would be for the year?

3 MS. VICARI: Object to form.

4 THE WITNESS: Yes.

5 BY MS. BAISCH:

6 Q All right. Elizabeth, from here on out
7 during the deposition, I'm going to tell you that
8 every question I ask I'm asking for your knowledge
9 during the time frame while you worked at AAPM.

10 Do you understand that?

11 A Yes.

12 Q And to the extent that there is an
13 objection other than to time frame, I want that
14 noted on the record from opposing counsel.

15 A Okay. Understood.

16 MS. BAISCH: Can you please tell me what
17 my last question was.

18 (Whereupon, the requested record
19 was read.)

20 BY MS. BAISCH:

21 Q Would the board of directors guide the
22 AAPM agenda for all AAPM conferences during the
23 time frame that you were at AAPM?

24 A No.

1 Q What do you mean by that?

2 A They delegated that responsibility to
3 other committees.

4 Q Can you give me an example?

5 A There was an annual conference
6 committee. They planned the agenda, identified
7 speakers, selected topics.

8 Q Was the annual conference committee made
9 up of members of the board of directors?

10 A There was overlap.

11 Q What do you mean by that?

12 A There were a few board members who were
13 also part of the -- the planning committee, but it
14 was not exclusively board members.

15 Q Who would determine -- or how would it
16 be determined who would be on the committee for
17 planning AAPM conferences?

18 A I don't know.

19 Q Do you know whether the committee would
20 have to be approved by the board of directors?

21 A I don't remember.

22 Q Do you know whether the committee would
23 have to be approved by the executive director of
24 AAPM?

1 A I don't -- I don't remember.

2 Q Would the board of directors determine
3 what information would be conveyed in the AAPM
4 magazine during the time frame that you were at
5 AAPM?

6 A The medical journal?

7 Q Yes.

8 A The medical journal had an editor-in-
9 chief who was a member of the board. I don't know
10 how they managed sourcing articles. I don't have
11 any insight into that.

12 Q Were articles for the medical journal
13 discussed during board of director meetings that
14 you attended?

15 A No.

16 Q Were any AAPM publications discussed
17 during board of director meetings that you
18 attended?

19 A That I -- I don't -- I don't know. It's
20 possible that they discussed a publication. I
21 don't remember.

22 Q Going back to the conflict of interest
23 committee, what was the conflict of interest
24 process at AAPM during the time frame that you

1 were employed at the AAPM?

2 A On an annual basis, board members would
3 complete, sign and submit a conflict of interest
4 form. And that would be held on record with the
5 association.

6 Q Did you ever review a conflict of
7 interest form during the time frame that you were
8 employed at the AAPM?

9 A What do you mean by "review"?

10 Q Did you have access to a -- the conflict
11 of interest forms?

12 A I did.

13 Q Did you ever look at the type of
14 information that was included on the form?

15 A Yes.

16 Q What type of information was included on
17 the conflict of interest form?

18 A Relationships with other organizations.
19 If you were -- if you received any -- if you had
20 either a financial or formal relationship with
21 another organization.

22 Q What do you mean by "formal"?

23 A Formal. So if you're a member of the
24 board of directors of a different organization,

1 or if you serve in -- if you serve as a staff
2 member at a particular organization.

3 Q Do you recall whether current employment
4 was included on the conflict of interest
5 disclosure form?

6 A I don't recall that.

7 Q Do you recall whether the -- you said
8 the form would disclose whether a member had a
9 financial relationship with another company?

10 A Yes.

11 Q Would the form ask what company, the
12 name of the company that a member had a financial
13 relationship with?

14 A Yes.

15 Q Would the form ask how much funding or
16 how -- or, I'm sorry, would the form ask what the
17 financial relationship was with the other company?

18 A I don't remember.

19 Q Do you recall what the revisions were to
20 the conflict form during the time frame that you
21 worked at AAPM?

22 A The -- I don't remember the specific
23 provisions.

24 Q Were you involved in the revision

1 process?

2 A I took direction from the chair of the
3 committee and from committee members.

4 Q Who was the chair of the committee that
5 you took direction from?

6 A Jerome Schofferman.

7 Q And what was the direction that you took
8 from Jerome Schofferman?

9 A I don't remember exactly. He would -- I
10 would redraft a question or redraft a portion
11 based on his direction.

12 Q Do you know who reviewed the completed
13 conflict of interest forms?

14 A No, I don't.

15 Q Do you know who verified that the
16 information on the forms was accurate?

17 A No, I don't know.

18 Q Do you know whether anybody did that?

19 A I don't know.

20 Q Do you know where the completed forms
21 were maintained at the AAPM?

22 A Yes. They were maintained both
23 electronically in the -- the shared folders for
24 the association, and they were also maintained in

1 paper form.

2 Q Did the AAPM have a document destruction
3 policy during the time frame that you worked
4 there?

5 A Yes.

6 Q Do you recall what it was?

7 A No.

8 Q Do you know how long the conflict of
9 interest forms would have been maintained?

10 A No.

11 Q Do you know how often documents were
12 destroyed at the AAPM?

13 A No.

14 Q Do you know who was responsible for
15 destroying documents at the AAPM?

16 MS. VICARI: Objection to form.

17 THE WITNESS: No.

18 BY MS. BAISCH:

19 Q Do you remember anything about what the
20 destruction -- the document destruction policy was
21 during the time frame that you were at AAPM?

22 A No. I -- I know there was a record
23 retention policy. I don't remember anything
24 beyond that.

1 Q Do you remember any documents being --
2 being shredded during the time frame that you were
3 at AAPM?

4 A Yes.

5 Q And tell me your recollection
6 surrounding the shredding of documents.

7 A We had storage space there, and we would
8 sometimes clean it out and throw away old
9 conference material.

10 Q Do you recall the time frame that you
11 considered when you determined what to throw out?

12 A No.

13 MS. VICARI: Objection to form.

14 BY MS. BAISCH:

15 Q During the time frame that you worked at
16 AAPM, who would you ask about the company's -- or,
17 I'm sorry, about the association's document
18 destruction policy?

19 A It was part of the policies and
20 procedures manual. I don't think I would have
21 asked anyone. I probably would have read that if
22 I had a need to.

23 Q During the time frame that you were at
24 AAPM, do you recall any occasion when an AAPM

1 member was not allowed to join the board of
2 directors because of a conflict of interest?

3 A No.

4 Q Do you recall any occasion when a member
5 of AAPM was not allowed to join a subcommittee
6 because of a conflict of interest?

7 A No.

8 Q Do you know how many board members --
9 how many AAPM board of director members had a
10 financial relationship with pharmaceutical
11 companies during the time that you worked for
12 AAPM?

13 MS. VICARI: Objection to form.

14 THE WITNESS: No, I don't know how many.

15 BY MS. BAISCH:

16 Q Do you know if it was more than half of
17 the board members?

18 MS. VICARI: Objection. Form.

19 THE WITNESS: I can't say that with
20 confidence. I don't know.

21 BY MS. BAISCH:

22 Q Who would you ask if you were still
23 working at AAPM about how many board members had a
24 financial relationship with pharmaceutical

1 companies during that time frame?

2 A I would ask the executive director of
3 the organization.

4 Q Would Jerome Schofferman have access to
5 that information to your knowledge?

6 A I don't know.

7 Q Did you ever have any conversations with
8 Jerome Schofferman about how many members of the
9 board of directors had a financial relationship
10 with pharmaceutical companies?

11 A No.

12 Q Did you ever have a conversation with
13 any members of the conflict of interest committee
14 about board members that had a financial
15 relationship with pharmaceutical companies?

16 MS. VICARI: Objection to form.

17 THE WITNESS: No. I was there to
18 provide administrative, not strategic, support.

19 BY MS. BAISCH:

20 Q Did anyone at AAPM ever express concern
21 that AAPM was reliant on industry funding?

22 MS. VICARI: Objection to form.

23 BY MS. BAISCH:

24 Q To you.

1 A Did I --

2 MS. VICARI: Same objection.

3 THE WITNESS: Did anyone say to me, I am
4 concerned? No.

5 BY MS. BAISCH:

6 Q Did anyone express any concern about
7 industry funding?

8 MS. VICARI: Objection to form.

9 THE WITNESS: Yes.

10 BY MS. BAISCH:

11 Q Tell me your recollection about that.

12 MS. VICARI: Same objection.

13 THE WITNESS: Jerome Schofferman
14 indicated some interest in decreasing the amount
15 of industry support. I heard -- I heard it said.

16 BY MS. BAISCH:

17 Q In your role as supporting the conflict
18 of interest committee during the time frame that
19 you worked at AAPM, did you ever revise a
20 conflict -- the conflict of interest form in a
21 fashion that would decrease the amount of support
22 that a board of director -- a member of the board
23 of directors could obtain from a pharmaceutical
24 company?

1 MS. VICARI: Objection to form.

2 THE WITNESS: No.

3 BY MS. BAISCH:

4 Q Do you know whether there was ever a
5 parameter set on the amount of support a board of
6 director could receive from a pharmaceutical
7 company?

8 A No.

9 Q No, you don't know or, no, you don't --
10 no, there wasn't one?

11 A No, there was not a parameter. The
12 disclosure said, For this amount or -- or above,
13 you must disclose. But it wouldn't exclude
14 someone from serving.

15 Q Do you know what the minimum disclosure
16 threshold was?

17 A No, I don't remember.

18 Q And to your knowledge, during the time
19 frame that you worked at AAPM, no one was
20 precluded from serving on the board of directors
21 as a result of receiving funding from a
22 pharmaceutical company?

23 A Correct.

24 Q Can you tell me what your understanding

1 is of the mission of the AAPM?

2 A The mission was, I believe, to connect
3 physicians in the same -- who were specializing in
4 the same field who had common professional
5 interests.

6 Q Do you agree that the AAPM had a
7 pro-opioid message when you were at AAPM?

8 MS. VICARI: Objection. Form.

9 THE WITNESS: No, because I don't know
10 what you mean by "pro-opioid."

11 BY MS. BAISCH:

12 Q Can you tell me what your understanding
13 was of AAPM's message with respect to opioids
14 during the time frame that you were at AAPM?

15 MS. VICARI: Objection to form.

16 THE WITNESS: Their position was that
17 it's one treatment option among other treatment
18 options.

19 BY MS. BAISCH:

20 Q What other types of treatment options?

21 A So one board member was doing something
22 around biofeedback; injections -- where you'd
23 receive injections of medications. Also an
24 interest in an integrative medicine approach, so

1 physical therapy, other types of treatment.

2 Q During the time frame that you were at
3 the AAPM, do you know whether the AAPM
4 communicated risks of opioid overdose?

5 MS. VICARI: Objection to form.

6 THE WITNESS: Yes, they did.

7 BY MS. BAISCH:

8 Q Do you know whether the AAPM
9 communicated risks of addiction to opioids?

10 MS. VICARI: Objection to form.

11 THE WITNESS: Yes, they did.

12 BY MS. BAISCH:

13 Q During the time frame that you worked at
14 the AAPM, did the AAPM consistently take a
15 position supporting access to opioids?

16 MS. VICARI: Objection to form.

17 THE WITNESS: Yes, they did.

18 (Tatum Exhibit No. 2 was marked
19 for identification.)

20 BY MS. BAISCH:

21 Q Elizabeth, I placed a document in front
22 of you that we've marked as Tatum document --
23 Exhibit No. 2.

24 Do you recognize the document I've

1 placed in front of you?

2 A I recognize the logos. I recognize the
3 logos, yeah, and I may have seen it during my time
4 there.

5 Q And at the top of the document, it
6 states that it's "The Use of Opioids For the
7 Treatment of Chronic Pain"; is that correct?

8 A Yes, that's correct.

9 Q And then under that it says: "A
10 consensus statement from the American Academy of
11 Pain Medicine and the American Pain Society."

12 A Yes.

13 Q And the American Academy of Pain
14 Medicine is the entity you worked for?

15 A Correct.

16 Q Can you turn to the last page of the
17 document. Do you see in the middle section where
18 it says: "This" -- or "The statement was prepared
19 by the following committee members"?

20 A Yes.

21 Q Can you take a look at that list, and
22 tell me whether you recognize any of the names on
23 that list as persons who were members of the AAPM
24 board of directors?

1 MS. VICARI: Object to the form.

2 THE WITNESS: Yes, Dr. Haddox. J. David
3 Haddox. And I believe Richard Blonsky. I think
4 he's now deceased.

5 BY MS. BAISCH:

6 Q Anybody else?

7 A I recognize names. I don't know if they
8 were on the board or not.

9 Q Do you recognize any of the names as
10 members of AAPM?

11 MS. VICARI: Objection to form.

12 THE WITNESS: I -- I don't -- I don't
13 know what the membership list was. I -- I would
14 imagine they were, but I don't know for sure.

15 BY MS. BAISCH:

16 Q Going back to the first page of the
17 document, can you look at the paragraph 1 that
18 says: "The management of pain is becoming a
19 higher priority in the United States."

20 Do you see that?

21 A Yes.

22 Q And do you see in the middle of that
23 paragraph where it starts: "These publications
24 which have been endorsed by AAPM and APS" -- do

1 you see that?

2 A Yes.

3 Q -- "state that opioids, sometimes called
4 narcotic analgesics, are an essential part of a
5 pain management plan."

6 Do you see that?

7 A Yes.

8 Q Would you agree that that message in the
9 sentence I just read, that "opioids are an
10 essential part of a pain management plan," was
11 consistent with the messages delivered by the AAPM
12 when you were at the AAPM?

13 MS. VICARI: Objection to form.

14 THE WITNESS: It feels -- that feels
15 like a very broad question. The organization made
16 lots of statements.

17 BY MS. BAISCH:

18 Q Do you recall the organization making
19 the statement that "opioids are an essential part
20 of a pain management plan"?

21 MS. VICARI: Object to the form.

22 THE WITNESS: I -- I'm reading it here.
23 I don't know whether that appeared in other
24 documents or publications.

1 BY MS. BAISCH:

2 Q Do you know whether the AAPM promoted
3 non-prescription drugs, drug treatments like
4 NSAIDs as a part of a pain management plan?

5 MS. VICARI: Objection to form.

6 THE WITNESS: Promoted? I know that
7 NSAIDs were considered part of the array of
8 options available to treat pain.

9 BY MS. BAISCH:

10 Q Do you recall any AAPM messages during
11 the time frame that you worked at AAPM that NSAIDs
12 are dangerous?

13 MS. VICARI: Objection to form.

14 THE WITNESS: There was a press release
15 or some kind of published statement that warned
16 about the dangers of taking too many NSAIDs, like
17 ibuprofen.

18 BY MS. BAISCH:

19 Q Do you recall any AAPM messages about
20 acetaminophen during the time frame that you were
21 at AAPM?

22 MS. VICARI: Objection to form.

23 THE WITNESS: Yes. I believe that
24 was -- acetaminophen is part of NSAIDs, I think.

1 BY MS. BAISCH:

2 Q That was your understanding of
3 acetaminophen?

4 A Yes. I honestly don't know.

5 Q Do you know -- other than opioids, do
6 you know what would also be an essential part of a
7 pain management plan?

8 MS. VICARI: Objection to form.

9 THE WITNESS: No. No. I'm not a -- I
10 don't have any --

11 BY MS. BAISCH:

12 Q I wasn't --

13 A -- healthcare training at all.

14 Q I wasn't asking for your personal
15 opinion.

16 A Yeah.

17 Q I was asking about the messages during
18 the time frame that you were at the AAPM. Do you
19 know whether the AAPM considered any other
20 pharmaceuticals an essential part of a pain
21 management plan?

22 MS. VICARI: Objection to form.

23 THE WITNESS: I -- I don't -- I don't
24 know. I remember mention of opioids and NSAIDs.

1 I don't know if there are other products.

2 BY MS. BAISCH:

3 Q And would -- was it your understanding
4 that opioids and NSAIDs were both essential parts
5 of a pain management plan?

6 MS. VICARI: Objection to form.

7 BY MS. BAISCH:

8 Q Based on the message of the AAPM?

9 MS. VICARI: Objection to form.

10 THE WITNESS: Their -- their position, I
11 believe, is that it was one part. It was one
12 piece or one option among other options.

13 BY MS. BAISCH:

14 Q Can you take a look at the next section:
15 "Current conditions dictate the need for a joint
16 consensus statement of two major national pain
17 organizations." Do you see that?

18 A Yes.

19 Q And the last sentence in that first
20 paragraph, do you see where it says: "Our
21 objective is for state policies to recognize but
22 not interfere with the medical use of opioids for
23 pain relief"?

24 A Yes.

1 Q Do you see that?

2 A Yes.

3 Q Was it your understanding that that
4 statement was consistent with messages that were
5 delivered by the AAPM while you were employed at
6 AAPM?

7 MS. VICARI: Objection to form.

8 THE WITNESS: Can I -- can I ask a
9 question?

10 BY MS. BAISCH:

11 Q I suppose so.

12 A I'm not sure what to make of -- when the
13 other attorney makes an objection.

14 MR. ENGLAND: Well, unless I tell you
15 not to answer the question, answer the question.

16 THE WITNESS: Okay.

17 Yes, that was -- that was consistent --
18 yes, that was consistent with the organization's
19 position.

20 BY MS. BAISCH:

21 Q That you recall -- just to clear that
22 up, during the time frame that you worked at AAPM,
23 you recall similar messages that were relayed by
24 AAPM that: "Our objective is for state policies

1 to recognize but not interfere with the medical
2 use of opioids for pain relief."

3 MS. VICARI: Objection to form.

4 THE WITNESS: Yes, similar messages.

5 BY MS. BAISCH:

6 Q Okay. Turning the page, going to
7 Section 4: "Current information and experience
8 suggests that many commonly held assumptions need
9 modification."

10 Do you see that?

11 A Yes.

12 Q The first sentence, "By addiction" --
13 and this is going to be the same question, is this
14 a similar message during the time frame that you
15 worked at AAPM that was relayed by AAPM, the first
16 sentence being: "Misunderstanding of addiction
17 and mislabeling of patients as addicts result in
18 unnecessary withholding of opioid medications"?

19 MS. VICARI: Objection to form.

20 THE WITNESS: It's -- so it's hard to
21 make a statement about these very specific --
22 about these very specific set of assumptions. The
23 organization had many trainings, many continuing
24 medical education sessions. I did not attend

1 those. I don't know the full scope of the
2 messages that they conveyed to their members.

3 BY MS. BAISCH:

4 Q Do you recall whether the statement,
5 "Misunderstanding of addiction and mislabeling of
6 patients as addicts results in unnecessary
7 withholding of opioid medications," do you recall
8 that being similar to the messages that you saw at
9 AAPM during the time frame that you were there?

10 MS. VICARI: Objection. Form.

11 THE WITNESS: It was -- yes, it was --
12 it was similar.

13 BY MS. BAISCH:

14 Q And then going to the next paragraph,
15 which starts with "Respiratory depression and
16 other side effects," in the second sentence, it
17 states: "It is now accepted by practitioners of
18 the specialty of pain medicine that respiratory
19 depression induced by opioids tends to be a
20 short-lived phenomenon, generally occurs only in
21 the opioid-naive patient and is antagonized by
22 pain."

23 Do you see that sentence?

24 A I do.

1 Q Do you recall whether that sentence is
2 consistent with messages by AAPM during the time
3 frame that you were at AAPM?

4 MS. VICARI: Objection to form.

5 THE WITNESS: I don't think it's
6 consistent with things I heard, no.

7 BY MS. BAISCH:

8 Q Is it similar to things that you heard
9 during the time frame that you were at AAPM?

10 MS. VICARI: Objection to form.

11 THE WITNESS: No.

12 BY MS. BAISCH:

13 Q The next sentence that says:
14 "Therefore, withholding the appropriate use of
15 opioids from a patient who is experiencing pain on
16 the basis of respiratory concerns is unwarranted."

17 Were you familiar with that -- that
18 statement during the time frame that you were at
19 AAPM?

20 A No.

21 Q Is that similar to statements that were
22 set out by AAPM during the time frame that you
23 were there?

24 MS. VICARI: Objection. Form.

1 THE WITNESS: No. There was -- there
2 were -- I only know this from reading titles,
3 because I didn't attend the sessions. But there
4 were continuing medical education sessions about
5 accidental overdose, and typically accidental
6 overdose, you know, was -- that resulted in death
7 was the result of respiratory depression. So I --
8 I don't think this is consistent.

9 BY MS. BAISCH:

10 Q In the next section that says
11 "Tolerance," in the second sentence is the
12 sentence: "Tolerance, or decreasing pain relief
13 with the same dosage over time, has not proven to
14 be a prevalent limitation to a long-term opioid
15 use."

16 Is that similar to messages that were
17 delivered by AAPM when you were at AAPM?

18 MS. VICARI: Objection to form.

19 THE WITNESS: I don't know the -- I
20 don't know.

21 BY MS. BAISCH:

22 Q And then in the last paragraph, the
23 second part of the first sentence where it says:
24 "Efforts to stop diversion should not interfere

1 with prescribing opioids for pain management."

2 Do you recall whether that message is
3 similar to messages from AAPM during the time
4 frame that you were at AAPM?

5 MS. VICARI: Objection. Form.

6 THE WITNESS: The organization, again, I
7 know from titles, had sessions about preventing
8 diversion, strategies for doing that like
9 prescription monitoring programs. So they -- they
10 talked about that as a -- a risk that had to be
11 managed.

12 BY MS. BAISCH:

13 Q Were you involved in any AAPM-sponsored
14 events that educated on the dangers of opioids?

15 A I'm sorry. Can you say the first part
16 again?

17 Q Were you involved in any AAPM-sponsored
18 events that educated on the dangers of opioids?

19 A Yes.

20 Q Do you recall how many times?

21 A I rarely attended those events. But I
22 helped to organize them.

23 Q Are you familiar with how AAPM is
24 funded?

1 A Generally, yes.

2 Q Do you recall what the annual budget was
3 during the time frame that you were at AAPM?

4 A No. Not the exact amount, no.

5 Q Do you know if it was more than a
6 million?

7 A Yes.

8 Q Do you know if it was less than
9 5 million?

10 A Yes.

11 Q Do you know if it was less than
12 3 million?

13 A No. I'm not sure.

14 Q During the time frame that you were at
15 AAPM, who was the person that was most familiar
16 with the funding of AAPM?

17 A The director of operations, the
18 executive director and the executive committee.

19 Q The executive committee of the board of
20 directors?

21 A Yes.

22 Q Do you know how much of the annual
23 budget came from pharmaceutical companies?

24 A No, I don't know how much.

1 Q Do you know roughly how much?

2 A No. Again, I could speculate. I don't
3 know.

4 Q Do you know whether the AAPM was
5 dependent on pharmaceutical companies for funding?

6 MS. VICARI: Objection to form.

7 THE WITNESS: What do you mean by
8 "dependent"?

9 BY MS. BAISCH:

10 Q Well, how was the -- how was AAPM
11 funded?

12 A AAPM was funded through membership fees,
13 through registrations for its annual conference,
14 from sponsorships associated with its annual
15 conference, and there may have been a couple of
16 other sources. Those are the main ones that I
17 remember.

18 Q Is the sponsorship for its annual
19 conference different from the payments that were
20 made to be on the Corporate Relations Council?

21 A I -- I know there was overlap. I don't
22 remember -- I don't remember exactly.

23 Q So other than the payments to be on the
24 Corporate Relations Council and sponsorship for

1 the annual conference, are you aware of any other
2 opportunities for pharmaceutical companies to
3 contribute to the AAPM fund?

4 A No.

5 Q Do you know when the -- when
6 pharmaceutical companies contribute to the AAPM
7 fund, do you know whether any third parties would
8 pay money on behalf of a pharmaceutical company?

9 MS. VICARI: Objection to form.

10 THE WITNESS: No, I -- no, I've never
11 heard of that.

12 Can we take a break for a few minutes?
13 I just need to use the restroom.

14 MS. BAISCH: Yep.

15 THE VIDEOGRAPHER: The time is
16 11:12 a.m., and we're going off the record.

17 (Recess.)

18 THE VIDEOGRAPHER: The time is 11:21
19 a.m., and we're back on the record.

20 (Tatum Exhibit No. 3 was marked
21 for identification.)

22 BY MS. BAISCH:

23 Q Elizabeth, I placed a document in front
24 of you that we've marked as Exhibit No. 3.

1 MS. NEWMARK: Counsel, we haven't
2 received that.

3 MS. BAISCH: Oh, I'm sorry.

4 BY MS. BAISCH:

5 Q Do you see in the cc line where it says
6 ElizabethTatum -- etatum@connect2amc.com?

7 A Yes.

8 Q And is that your e-mail address?

9 A Yes, it was.

10 Q In the text of the e-mail, do you see
11 it's an e-mail from Lynn Webster to Michael --
12 Michel Dubois?

13 MS. NEWMARK: Counselor, I'm going to
14 object to the use of this document. This document
15 is labeled "Confidential" pursuant to CMO No. 2.
16 I don't believe that Ms. Tatum has signed the
17 protective -- Exhibit A to the protective order.

18 MS. BAISCH: Paragraphs 43 and 44 of
19 CMO-2 say that if you're a recipient, an author or
20 if you've previously seen the document, it is not
21 confidential. And I have a copy of that with me
22 if you would like to confirm.

23 MS. NEWMARK: No, that's fine. Thank
24 you.

1 THE WITNESS: (Peruses document.)

2 BY MS. BAISCH:

3 Q Elizabeth, have you had an opportunity
4 to take a look at this e-mail?

5 A Yes.

6 Q In the middle of the sentence -- or, I'm
7 sorry, in the middle of the paragraph, do you see
8 where it says: "As far as REMS is concerned, we
9 have been on the lookout for what exactly FDA was
10 going to require. I don't think this is final
11 yet."

12 Do you see that?

13 A Yes.

14 Q Are you familiar with what that
15 discussion is about?

16 A REMS is the Risk Evaluation and
17 Mitigation Strategy. I believe it's a formal
18 program within the FDA.

19 Q Do you know what AAPM's role was with
20 respect to REMS during the time frame that you
21 were at AAPM?

22 A I believe the organization provided
23 comments about what the REMS would include.

24 Q Provided comments to who?

1 A I believe the FDA had an open comments
2 period. And the -- the organization may have also
3 released a statement or a position of some kind.
4 I don't remember exactly what, though.

5 Q Do you know who at AAPM would have
6 provided feedback on REMS during the time frame
7 that you were there?

8 MS. VICARI: Objection to form.

9 THE WITNESS: Members of AAPM.

10 BY MS. BAISCH:

11 Q Do you know if the board of directors
12 provided any feedback on REMS?

13 MS. VICARI: Objection to form.

14 THE WITNESS: Yes, I believe they did.

15 BY MS. BAISCH:

16 Q Do you know what type of feedback the
17 board of directors provided?

18 A No, I --

19 MS. VICARI: Objection to form.

20 THE WITNESS: -- don't remember.

21 BY MS. BAISCH:

22 Q Do you recall any discussions about the
23 physical examination requirement -- I'm sorry, the
24 physician examination requirement that's referred

1 to in the e-mail in front of you?

2 A I don't remember that discussion. I was
3 copied on the e-mail, but I don't remember a
4 discussion about that.

5 I remember a discussion about a
6 continuing medical education course but not a
7 certificate program.

8 Q What discussion do you remember about a
9 continuing education course?

10 A I remember the organization being
11 interested in providing -- providing that
12 continuing medical education or CME to physicians.

13 Q Just take one more look at the e-mail
14 that's in front of you. None of the people who
15 sent this e-mail, received this e-mail or were
16 copied on this -- who -- was anybody on this
17 e-mail not a member of the board of directors or a
18 staff member at AAPM?

19 A AAPM.

20 Q Yes, AAPM.

21 MS. VICARI: Objection to form.

22 BY MS. BAISCH:

23 Q Was anybody on this e-mail not on the
24 board of directors or a staff member at AAPM?

1 A All of them were at some point a member
2 of the board of directors. And then, yes, there
3 are also staff members.

4 (Tatum Exhibit No. 4 was marked
5 for identification.)

6 BY MS. BAISCH:

7 Q All right, Elizabeth, I placed in front
8 of you a document we've marked as Exhibit 4. And
9 do you see that this is an e-mail from Perry Fine,
10 and you are listed as one of the recipients?

11 A I just need a moment.

12 Q Yep.

13 A (Peruses document.) Yes, I see that.

14 MS. VICARI: Counsel, could we just have
15 a moment? There's a lot of pages to this exhibit.

16 (Pause in the proceedings.)

17 BY MS. BAISCH:

18 Q All right. Do you see in the first
19 e-mail, do you see where the name Malene Davis
20 appears?

21 A Yes.

22 Q Do you know who Malene Davis is?

23 A I -- I remember her now that I -- I see
24 her name. I know that she had some kind of

1 professional relationship with Dr. Fine. And is
2 it -- I don't even know if it was Malene. It
3 might have been Marlene.

4 Q Do you recognize that she was a member
5 at APF -- a board member at APF?

6 A I don't know who board members of APF
7 were.

8 Q Okay. Do you know who Lisa Robin is who
9 appears on this e-mail?

10 A I recognize the name. I don't know her.

11 Q Can you turn the second -- to the second
12 page at the bottom where you are sending the
13 e-mail to Scott Fishman, Lisa Robin, Perry Fine --

14 A Yes.

15 Q -- Will Rowe. Is that Humayun Chaudhry?

16 A Mm-hmm.

17 Q Is that a "yes"?

18 A Yes, I recognize that e-mail, yes.

19 Q And then J. Horowitz?

20 A Uh-huh. Yes, yes.

21 Q You're sending an e-mail confirming a
22 REMS alliance meeting; is that correct?

23 A Right.

24 Q Can you tell me what the REMS alliance

1 is?

2 A I -- I honestly don't remember what the
3 REMS alliance was. I know the organization was
4 interested in providing input on REMS. I don't --
5 I don't remember. I -- again, I was just
6 scheduling a meeting.

7 Q And did -- do you see that this meeting
8 was located at the FSMB office in Washington,
9 D.C.?

10 A Yes, I see that.

11 Q Did you attend the meeting at the FSMB
12 office?

13 A No, I did not.

14 Q Do you know what the connection was
15 between the FSMB and the REMS alliance?

16 MS. VICARI: Objection to form.

17 THE WITNESS: No. No, I can't remember
18 what the acronym stands for.

19 BY MS. BAISCH:

20 Q Did you attend --

21 A Or I guess it's here.

22 Q What do you mean, what acronym?

23 A FSMB.

24 Q Oh.

1 A I couldn't remember what it stood for,
2 but it's here. Federation of State Medical
3 Boards.

4 Q Do you recall having any other contact
5 with Lisa Robin of -- at FSMB?

6 A I may have sent again scheduling
7 e-mails.

8 Q Do you recall scheduling a lot of
9 meetings between FSMB and AAPM?

10 MS. VICARI: Objection to form.

11 THE WITNESS: No, I don't -- I don't
12 recall.

13 BY MS. BAISCH:

14 Q Did you ever attend a meeting with FSMB?

15 A I --

16 MS. YOCUM: Objection to form.

17 THE WITNESS: I may have. I don't -- I
18 don't know.

19 (Tatum Exhibit No. 5 was marked
20 for identification.)

21 BY MS. BAISCH:

22 Q Elizabeth, I placed a document in front
23 of you that we've marked as Exhibit 5. Do you see
24 where your name appears on the cc line of this

1 e-mail from -- from Phil Saigh?

2 A Yes.

3 MS. VICARI: Counsel, just to be clear,
4 what has been marked as Exhibit 5 is two
5 documents, the e-mail stapled together and --

6 MS. BAISCH: And the attachment to the
7 e-mail, that's -- that is correct.

8 BY MS. BAISCH:

9 Q Do you see that there's -- Exhibit 5
10 consists of the e-mail dated February 16, 2011,
11 and then the attachment to that e-mail, which is
12 American Academy of Pain Medicine Foundation? Do
13 you see that?

14 A I see that there's an attachment, but I
15 don't have that attachment.

16 Q Oh, I'm sorry.

17 MS. BAISCH: Do you have a stapler where
18 we can staple it all?

19 THE VIDEOGRAPHER: I'll find one in
20 there.

21 BY MS. BAISCH:

22 Q And just to be clear, the first document
23 starts at the bottom with a number on the bottom
24 of PPLP004349978. Do you see that?

1 A Yes, I do.

2 Q And then if you go through the four
3 pages consecutively, the last one, the last page
4 of the exhibit is PPLP004349981. Do you see that?

5 A Yes.

6 MS. BAISCH: Why don't we staple all
7 four of those pages.

8 BY MS. BAISCH:

9 Q We talked earlier today about the -- the
10 establishment of a foundation. Do you remember
11 that discussion?

12 A Yes.

13 Q Okay. And do you see the attachment to
14 the e-mail that is in front of you right now that
15 is Exhibit 5 --

16 A Yes.

17 Q -- is talking about an American Academy
18 of Pain Medicine Foundation?

19 A Yes.

20 Q Can you take a look at that -- that
21 memorandum and tell me if that is the same
22 foundation that we were talking about earlier.

23 A Yes, it is the same foundation that we
24 were talking about earlier.

1 Q And can you tell me the foundation
2 committee members that are listed at the bottom of
3 PPLP004349980, can you tell me whether you
4 recognize any of those names as persons who are on
5 the board of directors of AAPM?

6 A Yes.

7 Q All of them or just some of them?

8 A No, some of them. Lynn Webster at one
9 point. Michel DuBois, Rollin Gallagher, and Sean
10 Mackey.

11 Q And at the -- towards the top of that
12 same page where it says -- where it has the three
13 principal strategic initiatives, do you see that?

14 A Yes.

15 Q And it lists three: "Gaining primary
16 medical specialty recognition for pain medicine,
17 expanding breadth and scope of pain medication
18 education programs, and supporting pain medicine
19 research."

20 Is that consistent with your
21 understanding from the time frame that you were at
22 AAPM and what the foundation's strategic
23 initiatives were?

24 A Yes.

1 Q Do you know whether the foundation
2 promoted the use of opioids as an effective tool
3 for treating pain?

4 MS. YOCUM: Objection to form.

5 THE WITNESS: No, I don't know.

6 (Tatum Exhibit No. 6 was marked
7 for identification.)

8 BY MS. BAISCH:

9 Q All right, Elizabeth, I've placed a
10 document in front of you we've marked as Tatum
11 Exhibit 6, and do you see again where your name
12 appears in the cc line of this document?

13 A Yes.

14 Q And this is -- this is an e-mail from
15 Susie Flynn, who was the director of education
16 during the time that you were at AAPM?

17 A Yes.

18 Q And do you see that she is forwarding on
19 an e-mail from David Haddox?

20 A Yes, I see that.

21 Q And do you see that the -- the e-mail
22 from David Haddox appears to be a list of -- of
23 resources or literature. What would -- what would
24 you call that list that he is forwarding on?

1 A That seems accurate. Resources or
2 medical literature.

3 Q Was that a common practice during the
4 time frame that you were at AAPM to receive lists
5 of resources or literature from members of the
6 board of directors?

7 MS. VICARI: Objection to form.

8 THE WITNESS: I was an education
9 coordinator for a short period of time.
10 Otherwise, I don't remember -- I don't remember
11 seeing things like this. I wouldn't call it
12 common, no.

13 BY MS. BAISCH:

14 Q Do you know who David Haddox worked for?

15 A Yes.

16 Q Who did he work for?

17 A Purdue Pharmaceuticals.

18 Q Were you -- do you know what this list
19 was used for?

20 A No.

21 Q Do you know what the safe opioid
22 prescribing curriculum was?

23 A Yes.

24 Q What was that?

1 A That was a continuing medical education
2 conference organized and held by AAPM. From the
3 e-mail, it looks like -- just from the subject
4 line, it looks like these were materials for that
5 curriculum.

6 Q So who -- so was David Haddox preparing
7 the materials for that curriculum?

8 MS. VICARI: Objection to form.

9 THE WITNESS: I don't -- I don't know.

10 BY MS. BAISCH:

11 Q Do you know why else he would be sending
12 a list of resources and literature?

13 MS. VICARI: Objection to form.

14 THE WITNESS: No, I -- I don't --
15 typically there was a planning committee, and that
16 planning committee decided on content. I don't
17 know if he was part of the planning committee or
18 why they might have been exchanging this e-mail or
19 what his formal role was. I don't know.

20 BY MS. BAISCH:

21 Q Did the planning committee review -- to
22 your knowledge, did the planning committee review
23 the content of the programs?

24 A Yes.

1 (Tatum Exhibit No. 7 was marked
2 for identification.)

3 BY MS. BAISCH:

4 Q Elizabeth, a document that has been
5 identified as Exhibit 7 has been placed in front
6 of you. Do you see this is an e-mail from you to
7 Bobbie Sue Brown?

8 A Yes.

9 Q And can you just take a second to read
10 over the text of your e-mail to Mrs. Brown -- or,
11 I'm sorry, to Ms. Brown.

12 A (Peruses document.) Yes.

13 Q Was one of your responsibilities during
14 the time frame that you were at AAPM to send --
15 or, I'm sorry, to request grants from
16 pharmaceutical companies like Endo?

17 A Yes.

18 Q And is this e-mail confirming that you
19 submitted such a request through Endo's online
20 grant portal?

21 A Yes.

22 Q Do you recall whether Endo funded or
23 submitted any funds to AAPM during the time frame
24 that you were at AAPM?

1 MS. VICARI: Objection to form.

2 THE WITNESS: Yes.

3 BY MS. BAISCH:

4 Q Yes, you do recall?

5 A Yes, I do recall.

6 Q That they were one of the -- one of the
7 companies that submitted money to AAPM?

8 A Yes.

9 MS. VICARI: Objection to form.

10 BY MS. BAISCH:

11 Q Do you recall whether they were on
12 the -- the corporate council?

13 A No, I don't remember.

14 (Tatum Exhibit No. 8 was marked
15 for identification.)

16 BY MS. BAISCH:

17 Q Elizabeth, we placed in front of you a
18 document that's been identified as Tatum
19 Exhibit 8.

20 Do you see this is an e-mail that you
21 are sending to InfoUS?

22 A Yes.

23 Q And its subject is "AAPM Safe Opioid
24 Prescribing Initiative"?

1 A Yes.

2 Q Can you just take a few seconds to
3 review that e-mail.

4 A (Peruses document.) Yes.

5 Q Do you see in the last paragraph where
6 it says: "As Actavis is a member of the REMS
7 Industry Working Group, we would like to submit a
8 medical education grant application to Actavis for
9 support of this critical initiative"?

10 A Yes, I see that.

11 Q What is a medical education grant
12 application?

13 A It is a request for a grant to support a
14 continuing medical education program.

15 Q Do you know whether Actavis submitted a
16 grant to AAPM during the time frame that you were
17 at AAPM?

18 A I don't --

19 MS. VICARI: Objection. Form.

20 THE WITNESS: -- remember.

21 BY MS. BAISCH:

22 Q Do you know what the REMS Industry
23 Working Group was?

24 A No. I imagine it was a committee of

1 some kind, but I don't remember.

2 Q Do you know if Actavis funded AAPM in
3 any way during the time frame that you were at
4 AAPM?

5 A No, I don't know.

6 Q Were -- when you sent this e-mail, do
7 you recall whether you were working off a list of
8 REMS Industry Working Group members?

9 A I don't remember --

10 MS. VICARI: Objection to form.

11 THE WITNESS: I don't remember if I was
12 working off a list, no.

13 BY MS. BAISCH:

14 Q Do you remember why you were reaching
15 out to Actavis to submit a grant?

16 A No, I don't know why that company.

17 (Tatum Exhibit No. 9 was marked
18 for identification.)

19 BY MS. BAISCH:

20 Q All right, Elizabeth, we placed in front
21 of you Exhibit 9. Do you see this is an e-mail
22 that you are sending to Jackie Kim at Covidien?

23 A Yes.

24 Q Do you know whether Covidien provided

1 any funds to AAPM during the time frame that you
2 were at AAPM?

3 A Yes. Yes, they did.

4 Q Is this -- can you just tell me briefly
5 or in your own words how this worked that you
6 would send -- well, what was going on here? Take
7 a second to read this e-mail. You're sending a
8 grant -- a completed grant application to the
9 company?

10 MR. GOLDSTEIN: Object to the form.

11 THE WITNESS: Yes, I was sending a
12 completed grant application to the company.

13 BY MS. BAISCH:

14 Q And you are asking for additional -- an
15 additional grant?

16 MR. GOLDSTEIN: Object to the form.

17 MS. VICARI: Objection.

18 THE WITNESS: Well, it looks like from
19 the language of the e-mail, I'm revising the
20 initial application and submitting a new one.

21 BY MS. BAISCH:

22 Q Do you see in the third paragraph where
23 it says: "We would like to formally revise the
24 requested amount from \$250,000 to \$900,000 in

1 grant funding"?

2 A Yes.

3 Q Does that mean that you were -- is
4 that -- that's an increase in the request?

5 A Correct.

6 Q Okay. Do you know whether there was an
7 agreement for \$900,000 in grant funding from this
8 company?

9 MS. VICARI: Objection to form.

10 THE WITNESS: No. No, I don't think
11 there was.

12 (Tatum Exhibit No. 10 was marked
13 for identification.)

14 BY MS. BAISCH:

15 Q Elizabeth, going back briefly to
16 Exhibit 9.

17 A Yes.

18 Q When companies would pay grants to AAPM,
19 do you recall what entity it was paid to?

20 MS. VICARI: Objection to form.

21 THE WITNESS: I believe to the American
22 Academy of Pain Medicine.

23 BY MS. BAISCH:

24 Q Do you recall whether grants were also

1 paid to the foundation?

2 A I don't recall that. It's possible. I
3 don't remember.

4 Q Would grants -- to your knowledge, would
5 grants have been included in the -- in any
6 disclosure of total funding that AAPM received?

7 MS. VICARI: Objection to form.

8 THE WITNESS: Yes.

9 (Tatum Exhibit No. 10 was marked
10 for identification.)

11 BY MS. BAISCH:

12 Q All right. The next document that is in
13 front of you is Tatum Exhibit 10. Do you see that
14 is an e-mail that you are sending on November 8th,
15 2011?

16 A Yes.

17 Q And it is an e-mail with two
18 attachments.

19 A Yes.

20 Q Materials for planning committee and
21 C.A.R.E.S. Alliance?

22 A Yes.

23 Q Do you recall the SOP planning
24 committee?

1 A Yes. I recall that this was the
2 planning committee for the Safe Opioid Prescribing
3 Conference.

4 Q Do you recall -- recall who was the
5 chair for that committee?

6 A Dr. Lynn Webster was the chair.

7 Q And would the persons who are in the
8 recipient line of your e-mail, would those persons
9 have been on the committee for that conference,
10 that planning -- is that the planning committee?

11 A I don't remember the -- all the members
12 of the planning committee. Since I'm addressing
13 it to the planning committee members, it seems
14 like --

15 Q Right.

16 A -- that's probably what they are, but
17 I -- there may have been other people mixed in. I
18 don't know.

19 Q Can you flip forward to the fifth page,
20 which is page number 1 of the first attachment.
21 Do you see it says PPLP004345392 at the bottom?

22 A Yes.

23 Q And this appears to --

24 MS. VICARI: Just give me a second to --

1 the fifth page of the document?

2 MS. BAISCH: It's the first page of the
3 first attachment to the e-mail sent on
4 November 8th.

5 MS. VICARI: Thank you.

6 BY MS. BAISCH:

7 Q Do you see the list on that page?

8 A Yes.

9 Q Do you know whether this is a list of
10 the committee, the Safe Opioid Prescribing
11 Initiative planning committee?

12 A Yes. It looks like the list.

13 Q Do you recall the planning for this --
14 this conference?

15 A I have vague recollections of these
16 kinds of interactions, meetings, sending
17 materials, listening in on conference calls.

18 Q This was a -- this was a conference that
19 was scheduled for February of 2012 in Palm
20 String -- in Palm Springs, California?

21 A Yes, that sounds right.

22 MS. BAISCH: Oh, I marked the wrong one.

23 (Tatum Exhibit No. 11 was marked
24 for identification.)

1 BY MS. BAISCH:

2 Q All right, Elizabeth, we put in front of
3 you Exhibit 11, which is another e-mail sent from
4 you, and it appears to be another SOP planning
5 committee e-mail.

6 A Yes.

7 Q Do you see that?

8 A Mm-hmm.

9 Q And is it -- do you say SO Prescribing
10 planning committee?

11 A If I remember, we said SOP.

12 Q Okay.

13 A Yeah.

14 Q And I would like to look at the
15 attachments that you are sending out in this
16 e-mail, going all the way to the very last page of
17 the exhibit.

18 A Okay.

19 Q Do you see number 8, it says C.A.R.E.S.
20 Alliance?

21 A Yes.

22 Q Do you recall what that was?

23 A I recognize the name. I don't -- I
24 don't remember what that group was.

1 Q Do you know what number 9 means where it
2 says "Engagement with other stakeholders"?

3 A No.

4 Q Would you have been -- would you have
5 attended these planning meetings?

6 A Yes.

7 Q And then going to the third page of your
8 e-mail, there's another e-mail that you sent on
9 October 25th, 2011.

10 A Yes.

11 Q And number 2 in the e-mail that you're
12 sending, it says: "Complete the attached conflict
13 of interest disclosure statement." Do you see
14 that?

15 A Yes.

16 Q And you're sending that to the planning
17 committee members?

18 A Correct.

19 Q Do you know if that conflict of interest
20 disclosure statement would have been different
21 from the conflict of interest disclosure statement
22 that would've had to have been filled out by the
23 board of directors every year?

24 A I don't remember if it was the same or

1 if it was a different form.

2 Q Do you know who reviewed the disclosure
3 statements in connection with the SOP planning
4 committee?

5 A No, I don't know who reviewed them.

6 Q Do you know whether any persons on the
7 SOP planning committee -- any potential persons to
8 the SOP planing committee were disqualified as a
9 result of a conflict of interest?

10 A No, I --

11 MS. VICARI: Objection to form.

12 THE WITNESS: I don't remember anyone
13 being disqualified.

14 BY MS. BAISCH:

15 Q Do you remember whether all of the
16 members of the SOP planning committee submitted
17 their conflict of interest forms?

18 A It was my responsibility, I believe, to
19 collect those statements, and I -- I'm -- I don't
20 remember if anybody -- I imagine we followed --
21 typically our practice was to follow up and follow
22 up until we received the completed form.

23 Q When you received them, where would you
24 put them?

1 A I would save them to -- I would save
2 them within paper files, and then also typically
3 we got them electronically, so I would save them
4 electronically.

5 Q Would you notify anybody when you
6 received them?

7 A I would not notify anyone, no. I
8 probably had a checklist where I was checking off
9 who had submitted and who had not, and then
10 following up if someone had not submitted.

11 Q Do you know who -- do you know whether
12 anybody else ever looked at those conflict of
13 interest forms?

14 MS. VICARI: Objection to form.

15 THE WITNESS: I don't know. I don't
16 know.

17 BY MS. BAISCH:

18 Q If you were still at AAPM, who would you
19 ask about reviewing -- who reviewed the conflict
20 of interest forms for the SOP planning committee
21 for the February 2012 conference?

22 A I -- if I was still at AAPM, I would
23 probably ask Susie Flynn. I don't think she works
24 there any longer, but I probably would have asked

1 her, or I would have asked the committee chair.

2 Q Who was Lynn Webster?

3 A Yes.

4 Q Did you ever send any of the conflict of
5 interest forms to Lynn Webster?

6 A I don't remember doing that.

7 Q Do you recall ever sending them to
8 Susie?

9 A Susie had access to electronic files
10 that I had. I don't remember sending them to her,
11 though, specifically.

12 (Tatum Exhibit No. 12 was marked
13 for identification.)

14 BY MS. BAISCH:

15 Q All right, Elizabeth, we placed in
16 front of you what has been marked as Tatum
17 Exhibit 12. It is another e-mail that you sent on
18 November 10th, 2011. Do you see that?

19 A Yes.

20 Q And this e-mail also has an attachment
21 with it.

22 A Mm-hmm.

23 Q Is that a "yes"? Do you have the
24 attachment included in your exhibit?

1 A Yes, I do.

2 Q Okay. Going back to the text of the
3 e-mail, can you just take a second to read the
4 e-mail that you sent on November 10th.

5 A (Peruses document.) Yes.

6 Q All right. Do you see where you are
7 stating: "We are seeking to identify the correct
8 contacts at several companies which may be
9 interested in offering medical education grants
10 for the SOP -- SO prescribing program"?

11 A Yes, I see that.

12 Q "And then in the attached spreadsheets
13 of the companies we need correct contacts for are
14 highlighted in yellow."

15 A Yes, I see that.

16 Q Do you recall the -- the discussion that
17 led -- led to you sending this list out?

18 MS. VICARI: Objection to form.

19 THE WITNESS: No, I don't remember that
20 discussion.

21 BY MS. BAISCH:

22 Q Did you maintain the list that is
23 attached as the list of pharma contacts? The list
24 that you're sending out attached to this e-mail,

1 was that something that you maintained?

2 A Yes.

3 Q Do you know whether this is a list of
4 companies that provided funds to AAPM at one
5 occasion during the time frame that you were at
6 AAPM?

7 MS. VICARI: Objection to form.

8 THE WITNESS: No, I can't say that with
9 any confidence.

10 BY MS. BAISCH:

11 Q Do you know whether this is a list of --
12 well, do you know what -- how you created this
13 list?

14 A No. I don't -- I'm looking at the list.
15 So there's a heading that says "Companies with an
16 established relationship with AAPM." I imagine
17 those were organizations that provided us with
18 funding. Companies without a previous connection
19 to AAPM, I don't know how those got on the list.

20 Q Can you just take a second to look at
21 the list. The -- the first page of the attachment
22 that you're sending in this e-mail, does this
23 refresh your memory as to whether Endo contributed
24 funds to AAPM during the time frame that you were

1 at AAPM?

2 A Yes, I believe they -- they did provide
3 funding. How --

4 Q Do you --

5 A How much and for what, I don't remember.

6 Q Do you remember whether Cephalon
7 provided funding during the time frame that you
8 were at AAPM?

9 A Yes.

10 Q Do you remember whether Janssen provided
11 funding during the time frame that you were at
12 AAPM?

13 A I am not sure.

14 Q Do you know whether Mallinckrodt
15 provided funding during the time frame that you
16 were at AAPM?

17 A Yes.

18 Q Do you remember whether Pfizer provided
19 funding during the time frame that you were at
20 AAPM?

21 A Yes.

22 Q Do you remember whether Purdue Pharma
23 provided funding at -- during the time frame that
24 you were at AAPM?

1 A Yes.

2 Q Do you know why -- do you recall why
3 Janssen is in gray here versus the green?

4 A No.

5 Q Do you recall whether the --

6 A Bad administrative practice.

7 Q -- what the -- do you recall what the
8 yellow meant?

9 A I see from my e-mail what I said. And
10 according to the e-mail, it says: "The companies
11 we need correct contacts for are highlighted in
12 yellow." So I imagine it's because we didn't have
13 contacts at those companies.

14 Q Can you take a second to look at this
15 list and tell me whether you recall, now that you
16 have this list in front of you, whether any of the
17 other companies on this list provided funds during
18 the time frame that you were at AAPM, funds to
19 AAPM.

20 A No, I don't know if any of these
21 companies provided funding.

22 Q Do you know whether any of these
23 companies were on the -- the -- what was it
24 called, the initiative -- the company initiative

1 committee?

2 MS. VICARI: Objection to form.

3 BY MS. BAISCH:

4 Q I'm sorry, the -- the council --

5 A The Corporate Relations Council?

6 Q Yes, that's it.

7 A No, I don't remember.

8 Q Going back to the text of your e-mail,
9 do you see in the second paragraph where you say:
10 "While I read through the list of REMS Industry
11 Working Group members"? Do you recall what that
12 list was?

13 A No, I -- I don't.

14 Q When you were getting -- when you were
15 involved in the planning for meetings like this
16 SOP meeting that was going to happen in February
17 of 2012, was this something that you would have
18 been responsible for, reaching out to these
19 entities to seek grants?

20 A That was my --

21 MS. VICARI: Objection to form.

22 THE WITNESS: That was my responsibility
23 for this conference, yes, was preparing and
24 submitting grants.

1 BY MS. BAISCH:

2 Q Do you recall whether any of the
3 companies you reached out to did not submit
4 grants?

5 A No, I don't remember.

6 Q Meaning that --

7 A I don't know -- I can't remember which
8 companies provided grants and which ones did not
9 provide grants.

10 Q So it is possible that a company did not
11 provide a grant?

12 A Yes.

13 (Tatum Exhibit No. 13 was marked
14 for identification.)

15 BY MS. BAISCH:

16 Q All right, Elizabeth, you have in front
17 of you a document that has been marked as
18 Exhibit 13; is that correct?

19 A Yes.

20 Q And this is an e-mail that you're
21 sending on January 19th, 2012?

22 A Yes.

23 Q And it -- it says, "Presentation
24 Materials: Due February 1st," but does this also

1 relate to that same SOP planning committee?

2 A Yes.

3 Q For the February 2012 conference?

4 A Yes.

5 Q And do you see in the instruction
6 section that you're providing, there's some
7 bullets in the text of your e-mail? Do you see
8 the bullets?

9 A Yes, I do.

10 Q And then in the second line it says:
11 "Timeline: All presentation materials are due by
12 February 1st," and then send to
13 etatum@connect2amc.com.

14 A Yes, I see that.

15 Q And that is -- that's your e-mail
16 address?

17 A Yes, it was at that time.

18 Q When you received the present --
19 presentation materials, what would you do with
20 them?

21 MS. VICARI: Objection to form.

22 THE WITNESS: I probably filed them
23 away.

24 MS. VICARI: Counsel, just for the

1 record, from the e-mail there are -- one, two,
2 three, four -- five attachments, but I think
3 there's only three included in the exhibit.

4 MS. BAISCH: For the record, attachment
5 1 and attachment 2 were withheld as nonresponsive
6 by defense.

7 MS. VICARI: Okay.

8 MS. BAISCH: And the other three
9 attachments are included here.

10 BY MS. BAISCH:

11 Q And what did you -- I'm sorry, when you
12 received the presentation materials, where -- you
13 were saying, where did you save them?

14 A I believe I saved them to the shared
15 file for AAPM.

16 Q And do you know whether anybody within
17 AAPM would have reviewed them?

18 A I --

19 Q Any of the staff members.

20 A I believe staff members would have
21 reviewed them with members of the planning
22 committee. Yes, I imagine that. Yeah.

23 (Tatum Exhibit No. 14 was marked
24 for identification.)

1 BY MS. BAISCH:

2 Q All right. We put another exhibit in
3 front of you, and it's marked as Exhibit 14. Is
4 that correct?

5 A Yes.

6 Q And it is another e-mail sent by you on
7 January 27th, 2012?

8 A Yes.

9 Q And this also relates to presentation
10 materials for the February 2012 SOP conference?

11 A Yes.

12 Q And this e-mail has -- on the first
13 page, it references four attachments. Do you see
14 that?

15 A Yes.

16 Q But the exhibit in front of you only has
17 two attachments included with it.

18 A Mm-hmm.

19 Q Is that a "yes"? Why don't you
20 double-check that.

21 A Yeah. (Peruses document.)

22 Q The first being the handout
23 instructions?

24 A And then the timeline, yep.

1 Q And then being the timeline.

2 A Yep.

3 Q Can you tell me -- looking back at
4 Exhibit 13, can you tell me whether the handout
5 instructions and the timeline for handout
6 submission, to your knowledge, are the documents
7 that are attached to Exhibit 14, would those have
8 been the same ones you would have attached in
9 Exhibit 13?

10 A Yes, that seems -- that seems likely.

11 Q Would there have been any reason that
12 you would have made any changes to the handout
13 instruction and the timeline for handout
14 submission between the time frame of
15 January 1st -- I'm sorry, January 19th, 2012,
16 which is the date of Exhibit 13, and January 27th
17 of 2012, which is the date of Exhibit 14?

18 A Yes, it's very possible I made changes
19 in between. I wasn't particularly good at version
20 control back then.

21 Q Can you take a look at the attachment,
22 the handout instructions attachment to this
23 e-mail.

24 A Yes. (Peruses document.)

1 Q Just -- it's a two-page document. Can
2 you tell me whether this handout instructions
3 document is consistent with a document that would
4 be used for handouts for any AAPM conference
5 versus being unique to this one?

6 MS. VICARI: Objection to form.

7 THE WITNESS: I can't -- I -- I don't
8 know. This was the only conference -- the only
9 CME program that I personally helped put together
10 from a logistics standpoint. So I don't know what
11 those other submission requirements would look
12 like.

13 BY MS. BAISCH:

14 Q Do you recall making any changes to this
15 document?

16 A I don't recall, no.

17 Q At the bottom of the first page that
18 ends in PPLP004353082, do you see where it says:
19 "Items that should not be included"?

20 A Yes.

21 Q And you see the second bullet that says:
22 "Trade names. Whenever generic names can be used
23 when discussing pharmaceutical agents or medical
24 devices and products. If trade names are used,

1 include the names of products made by more than
2 one manufacturer."

3 Do you see that?

4 A Yes, I do.

5 Q Do you know why that was included in the
6 handout instructions?

7 A No, I don't. I don't know if that was
8 an organizational requirement; if that was
9 standard practice or a requirement for continuing
10 medical education --

11 Q Do you know --

12 A -- or -- I really don't know.

13 Q Do you know who -- do you know who
14 prepared the handout instructions?

15 A I prepared them, but I would not have --
16 I would have prepared a draft, and then it would
17 have been reviewed by the director of education,
18 and potentially by the committee chair as well.

19 Q Do you know whether anybody checked,
20 like reviewed the handout specifically for the use
21 of generic names versus trade names?

22 MS. VICARI: Objection to form.

23 THE WITNESS: I don't know.

24 BY MS. BAISCH:

1 Q And then on the last page of this
2 handout instructions attachment, do you see at the
3 top where it says "Review process," and then it
4 says "The content review committee"?

5 A Yes.

6 Q Do you know who would have been on the
7 content review committee?

8 A No.

9 Q Would that have included the chair of
10 the -- of the SOP planning committee?

11 MS. VICARI: Objection to form.

12 THE WITNESS: I'm not -- I'm not sure.
13 I don't remember the composition of that
14 committee.

15 (Tatum Exhibit Nos. 15 and 16 were
16 marked for identification.)

17 BY MS. BAISCH:

18 Q All right. Now, so, Elizabeth, there
19 are two exhibits in front of you right now.
20 Exhibit 15, which is a February 17th e-mail from
21 David Haddox to you, and Exhibit 16, which is a
22 February 16th e-mail from -- from you to David
23 Haddox.

24 Do you see that? I'm sorry, no, from

1 David Haddox to you.

2 A Yes, I see that. Yep.

3 Q All right. And looking first at
4 Exhibit 16, can you just -- going back to the very
5 last page of this exhibit, which is PPLP004351951.

6 A Yes.

7 Q Do you see at the top there is an e-mail
8 from Susie Flynn to David Haddox, and you are
9 cc'd?

10 A I believe it's from David Haddox to
11 Susie Flynn -- or am I looking at the wrong one?
12 I'm looking at the wrong one.

13 Q Exhibit --

14 A Yes, I see -- I see that, yep, the last
15 page.

16 Q And you see where she says: "Can you
17 please confirm your ability to participate in the
18 regular -- regulatory response lecture?"

19 Do you see that paragraph?

20 A Yes.

21 Q Okay. So this -- Susie here is just
22 confirming that he is going to be a presenter in
23 one of the lectures of that SOP conference?

24 A Yes.

1 Q And this again -- what is the faculty
2 agreement and attestation form? Is that just --

3 A I don't know what that includes.

4 Q Do you know whether you received it from
5 David Haddox?

6 A Probably. I believe all faculty members
7 had to complete an agreement and attestation form.
8 So I -- again, I probably collected the document.

9 Q Going forward two pages to the e-mail
10 sent on February 13th, 2012, from David Haddox to
11 Susie Flynn, where you are cc'd, do you see that?

12 A Yes.

13 Q And do you see in the -- the very first
14 paragraph that he's saying that: "I will send my
15 slides for AA -- AAPM review ASAP, but I will not
16 submit them to our internal review until AAPM
17 signs off on the content to prevent our reviewers
18 from having to review it, and, if need be, accept
19 changes from AAPM necessitating a second review"?

20 A Yes, I see that.

21 Q Are you familiar with the review process
22 that he is talking about?

23 A No, I'm not.

24 Q Do you know what he means by "our

1 reviewers"?

2 MS. VICARI: Objection to form.

3 THE WITNESS: I -- I don't -- it looks

4 like he's referring to members of his company.

5 But I don't -- I honestly don't know.

6 BY MS. BAISCH:

7 Q And if you go up to the e-mail that
8 you're sending, the next e-mail above that,
9 February 14th, 2012, that you're sending to
10 David -- David Haddox?

11 A Yes.

12 Q In the very last paragraph of that
13 e-mail, you're stating: "I will seek a quick
14 turnaround from our reviewers after your slide
15 decks have been submitted. Once all of the review
16 processes from the AAPM and Purdue perspectives
17 have been completed, I will place your content
18 into our branded PPT template."

19 Do you see that?

20 A Yes.

21 Q Does that help clarify what "our
22 reviewers" means?

23 A Yes.

24 Q And --

1 A Yes.

2 Q And what is your understanding of what
3 "our reviewers" means?

4 A Reviewers from the company that employed
5 him, Purdue Pharmaceuticals.

6 Q And if you -- going now to Exhibit 15,
7 which is the e-mail chain that starts on
8 February 17th, at the top of that exhibit.

9 A Yes.

10 Q Do you see that?

11 A Yes.

12 Q Okay. Do you see at the second page,
13 there's an e-mail sent February 17th from David to
14 Susie, and you are cc'd?

15 A It's not clear that I'm --

16 Q I think it starts at the bottom of --
17 let's just do this. Go to the e-mail that David
18 is sending to Susie, the last e-mail.

19 A Uh-huh. The one on -- oh, the very last
20 e-mail.

21 Q Yeah, the very last e-mail.

22 A Yep.

23 Q "Sounds like a plan."

24 A Yep.

1 Q "Our review has started." Do you see
2 that?

3 A Yes, uh-huh.

4 Q In the context of this e-mail, is it
5 your understanding that that is a review being
6 conducted by David Haddox's company, Purdue?

7 A Yes.

8 (Tatum Exhibit No. 17 was marked
9 for identification.)

10 BY MS. BAISCH:

11 Q All right, Elizabeth, is -- do you have
12 Exhibit 17 in front of you now?

13 A Yes.

14 Q Do you recognize this document?

15 A Yes, I do.

16 Q Is this the brochure for the SOP
17 conference that we've been talking about in
18 February 2012?

19 A Yes.

20 Q And can you turn to the third page of
21 this brochure where it says "Commercial Support"?

22 A Yes.

23 Q Did you know -- or, I'm sorry, does
24 the -- the entities that are listed here, the

1 companies that are listed here, does this mean
2 that they provided funding to AAPM?

3 A Yes.

4 Q And does --

5 A To support this specific program.

6 Q And does the -- at the top where it says
7 "Four Star Diamond," does that mean that they
8 would have paid more money than the next line, the
9 diamond?

10 A Yes.

11 Q And do you recall what the distinction
12 was between the different levels that are set out
13 here?

14 A No, I don't remember the dollar amount.

15 Q If an entity provided funding for this
16 conference, do you know if there was a level --
17 another level that they wouldn't have appeared on
18 the brochure?

19 A I don't remember.

20 MS. BAISCH: All right. I'm going to
21 take a break.

22 THE VIDEOGRAPHER: The time is 12:23
23 p.m. We're going off the record.

24 (Recess.)

1 THE VIDEOGRAPHER: The time is 12:42
2 p.m., and we're back on the record.

3 BY MS. BAISCH:

4 Q All right, Elizabeth, did Webster --
5 Lynn Webster, did he have a significant role in
6 the AAPM?

7 MS. VICARI: Objection to form.

8 THE WITNESS: Yes.

9 BY MS. BAISCH:

10 Q Was he influential on the direction of
11 the AAPM?

12 MS. VICARI: Objection to form.

13 THE WITNESS: At one point he was
14 president of the board of directors. So, yes.

15 BY MS. BAISCH:

16 Q Did David Haddox have a big role in -- a
17 significant role in AAPM?

18 MS. VICARI: Objection to form.

19 THE WITNESS: Not -- his position on the
20 board was different. I don't believe he was a
21 member of the executive committee.

22 BY MS. BAISCH:

23 Q Do you know whether he was influential
24 in the direction of the AAPM?

1 MS. VICARI: Objection to form.

2 THE WITNESS: I can't assess that.

3 BY MS. BAISCH:

4 Q Did anyone ever express concern about
5 the financial connection between pharmaceutical
6 companies and members of the board of directors?

7 MS. VICARI: Objection to form.

8 THE WITNESS: I heard people express
9 concern.

10 BY MS. BAISCH:

11 Q Who did you --

12 A Verb -- verbally.

13 Q Who did you hear express concern?

14 A I remember Jerome Schofferman expressing
15 concern.

16 Q And what concern was expressed?

17 A That the organization needed to
18 diversify its sources of funding so that industry
19 funding was a smaller portion of its overall
20 budget.

21 Q Do you -- do you recall what industry
22 funding -- what the budget -- the percentage of
23 the budget was from industry fund -- funding?

24 A No, I don't.

1 MS. VICARI: Objection to form.

2 BY MS. BAISCH:

3 Q Did anyone else ever express concern
4 about the financial connection between
5 pharmaceutical companies and members of the board
6 of directors?

7 MS. VICARI: Objection. Form.

8 THE WITNESS: No, I don't remember
9 anyone else expressing concern.

10 BY MS. BAISCH:

11 Q Do you recall Susie Flynn ever
12 expressing concern about the financial connection
13 between members of the board of directors and
14 pharmaceutical companies?

15 A Yes.

16 MS. VICARI: Object to form.

17 THE WITNESS: I remember her saying to
18 me privately that she had concerns.

19 BY MS. BAISCH:

20 Q What concerns did Susie Flynn have?

21 MS. VICARI: Objection. Form.

22 THE WITNESS: Nothing specific, just
23 she noted the fact that members of the board of
24 directors had relationships with the

1 pharmaceutical industry.

2 BY MS. BAISCH:

3 Q Do you know whether Dr. Schofferman ever
4 did anything about his concerns?

5 A He led the conflict of interest
6 committee and revised the form, the conflict of
7 interest disclosure form, which I believe we
8 talked about earlier. And I think he -- he asked
9 the question about diversifying the organization's
10 funding, and attempted to generate a discussion,
11 but nothing beyond that.

12 Q Do you know whether the AAPM's funding
13 was ever diversified during the time frame that
14 you were at AAPM?

15 MS. VICARI: Objection to form.

16 THE WITNESS: No.

17 BY MS. BAISCH:

18 Q Did -- yeah, no, you don't -- no, it
19 wasn't?

20 A No, it was not diversified.

21 Q So there were no changes with respect to
22 the -- the funding that AAPM received from
23 pharmaceutical companies during the time frame
24 that you were at AAPM?

1 A No, I don't believe so. It was
2 fairly -- it was fairly consistent. Again,
3 that's speaking very generally. I don't remember
4 percentages.

5 Q Do you know if anyone ever expressed
6 concern about the financial connection between
7 AAPM and pharmaceutical companies?

8 MS. VICARI: Objection. Form.

9 THE WITNESS: Other than the two people
10 I've already mentioned, no.

11 BY MS. BAISCH:

12 Q When we were talking about
13 Dr. Schofferman and Susie Flynn, were they
14 expressing concern about members of the board of
15 directors or were they expressing concern about
16 AAPM in general?

17 MS. VICARI: Objection. Form.

18 THE WITNESS: Susie was expressing
19 concern about members of the board.

20 Dr. Schofferman, those are his
21 colleagues, I don't think he would have done that.
22 I think he was asking the question generally about
23 the organization.

24 (Tatum Exhibit No. 18 was marked

1 for identification.)

2 BY MS. BAISCH:

3 Q Elizabeth, we put in front of you a
4 document that has been labeled as Exhibit 18. It
5 is a letter. Are you -- are you familiar with
6 this -- this letter?

7 A Honestly, I -- I don't -- I don't
8 remember seeing this letter. Although this was
9 during my time of employment, I don't remember
10 seeing this.

11 Q All right. So the date of the letter is
12 May 8th, 2012?

13 A Yes.

14 Q And it's from the United States Senate
15 Committee on Finance?

16 A Yes.

17 Q And it's addressed to who?

18 A Mart -- Martin Grabois.

19 Q Did you know Martin?

20 A Yes, as the president of the -- the
21 board of AAPM.

22 Q And he was president during the time
23 frame that you were there?

24 A Yes.

1 Q And you don't recall -- you don't recall
2 seeing this letter before?

3 A No. I may have seen it before, but I
4 don't -- I don't remember.

5 Q Can you just go to the third page of the
6 letter where it says -- there's a list that says:
7 "Please provide the following information," and
8 then it lists off 1, 2, 3, 4, 5.

9 A Yes, I see that.

10 Q Does that help refresh your memory as to
11 whether you've seen this letter before?

12 A No. Again, it's very possible. I -- I
13 may have even helped respond to the letter, but
14 I -- I don't remember.

15 Q Do you remember -- do you remember the
16 United States Senate Committee on Finance
17 requesting information from AAPM?

18 A No, I don't remember that.

19 Q Do you -- were you aware that the United
20 States Senate Committee on Finance conducted -- or
21 conducted an investigation in which it requested
22 information from AAPM?

23 MS. VICARI: Objection to form.

24 THE WITNESS: Honestly, no. I mean

1 that's embarrassing, it's the Senate, but I -- I
2 honestly don't remember.

3 (Tatum Exhibit No. 19 was marked
4 for identification.)

5 BY MS. BAISCH:

6 Q I'm placing in front of you Exhibit 19.
7 It is a report -- at the bottom you see it says
8 U.S. Senate Homeland Security and Governmental
9 Affairs Committee?

10 A Yes.

11 Q And then it's called "Fueling An
12 Epidemic, Report Two, Exposing the Financial Ties
13 Between Opioid Manufacturers and Third Party
14 Advocacy Groups." Do you see that?

15 A Yes.

16 MS. VICARI: Counsel, we seem to have
17 two different documents. I just want to make sure
18 we're all looking at the right one.

19 MR. GOLDSTEIN: Is this part of the
20 exhibit?

21 MS. BAISCH: Oh, no, that's not part of
22 the exhibit. Sorry.

23 BY MS. BAISCH:

24 Q Have you ever seen this document before?

1 A No, I have not.

2 Q Does this help refresh -- refresh your
3 recollection as to whether the Senate conducted an
4 investigation that involved AAPM?

5 A No.

6 MS. VICARI: Objection. Form.

7 MS. BAISCH: All right, we'll turn the
8 microphone over to whoever may need it.

9 We don't have any further questions for
10 you at this time.

11 THE WITNESS: Okay.

12 MS. VICARI: We'll just go off the
13 record for a minute.

14 THE VIDEOGRAPHER: Yes. The time is
15 12:52 p.m., and we're going off the record.

16 (Pause in the proceedings.)

17 THE VIDEOGRAPHER: The time is 12:54
18 p.m., and we're back on the record.

19 CROSS-EXAMINATION

20 BY MS. VICARI:

21 Q Ms. Tatum, thank you for your time and
22 your patience today.

23 My name is Angela Vicari. I'm with the
24 law firm Arnold & Porter, and I represent Endo

1 and -- the Endo and Par defendants in this
2 litigation.

3 We've never met before today's
4 deposition, correct?

5 A Correct.

6 Q And we've never spoken before today's
7 deposition?

8 A Correct.

9 Q You testified earlier about being
10 contacted by someone named Desiree Torres from
11 Griffin Strategies.

12 Do you recall that?

13 A Yes.

14 Q And Ms. Torres told you that she was
15 hired by a law firm?

16 A Yes.

17 Q Do you know what law firm hired her?

18 A Motley Rice.

19 Q What was your understanding of the
20 nature of Ms. Torres's investigation?

21 A I -- I didn't understand it, honestly.
22 She didn't really explain it to me. She asked a
23 series of questions but didn't explain the nature
24 of her -- the investigation fully.

1 Q Do you recall any of the questions that
2 she asked you?

3 A She asked me some of the questions I've
4 been asked today about the conflict of interest
5 form, about members of the board and their
6 relationships to pharmaceutical companies. That's
7 what I remember.

8 Q And did you tell her anything different
9 than what you testified about here today?

10 A I think we had -- we had -- ended up
11 having a number of conversations, and I -- I may
12 have said different things during that
13 conversation. It was a different kind of
14 interaction.

15 Q How so?

16 A It was less structured and less formal.

17 Q So how many -- how many conversations
18 did you have with Ms. Torres?

19 A I can't say. Maybe -- maybe three,
20 maybe four. It was several.

21 Q When you said that one was less
22 structured, which one was less structured?

23 A All of the conversations with her were
24 less structured than what we've had today.

1 Q I see. Did Ms. Torres tell you whether
2 she contacted other current or former employees of
3 AAPM?

4 A No. I asked her that question. I did
5 not get a clear answer.

6 Q So you don't know whether she did
7 contact anyone else from AAPM?

8 A No, I don't know.

9 Q Did Ms. Torres tell you whether she
10 spoke to anyone else regarding opioid litigation?

11 A It was clear she was speaking to the
12 attorney at Motley Rice, Linda Singer. I don't
13 know -- I don't remember her mentioning speaking
14 to anyone else.

15 Q And you mentioned a statement that
16 Ms. Torres asked if you had signed. Do you recall
17 that?

18 A Yes, she asked me to sign a declaration.
19 That's the term that she used.

20 Q Did you ever see a declaration?

21 A I did.

22 Q How did you come about seeing the
23 declaration?

24 A She sent it to me in an e-mail.

1 Q When you say "she," who are you
2 referring to?

3 A Desiree Torres.

4 Q Do you know who drafted the e-mail --
5 sorry, do you know who drafted the declaration?

6 A She drafted the declaration.

7 Q Did you review the declaration that she
8 provided you over e-mail?

9 A Yes, I did.

10 Q Do you still have a copy of the
11 declaration?

12 A Yes, I do.

13 Q And in what form?

14 A I believe it's either a Word document or
15 a PDF.

16 Q And you did not sign the declaration
17 that Ms. Torres sent you?

18 A Correct, I did not sign it.

19 Q Did Ms. Torres put pressure on you to
20 sign it?

21 MS. DICKINSON: Objection. Form.

22 THE WITNESS: No.

23 BY MS. VICARI:

24 Q Did you feel any pressure to sign it?

1 A No.

2 Q Did Ms. Torres say whether anyone else
3 from AAPM signed a declaration?

4 A No, she did not.

5 Q Did Ms. Torres say whether anyone else
6 signed a declaration regarding the opioid
7 litigation?

8 A She did not say.

9 Q Did Ms. Torres provide you with any
10 documents other than the declaration that she sent
11 to you via e-mail?

12 A No.

13 Q Approximately when did she send the
14 declaration via e-mail?

15 A It was sometime during the summer. I
16 think towards the beginning of the summer of 2018.

17 Q Approximately how many times did you
18 speak with Ms. Torres before she sent you the
19 declaration?

20 A Three to four times.

21 Q Other than the e-mail by which
22 Ms. Torres transmitted the declaration that we've
23 been talking, did you -- that we've been talking
24 about, did you have any other written

1 communications with Ms. Torres?

2 A No.

3 Q Did you have any written communications
4 with anyone from Griffin Strategies other than
5 Ms. Torres?

6 A No.

7 Q Let's turn briefly just to -- to your
8 role at AAPM.

9 Would you categorize -- would you
10 describe yourself as an administrative employee of
11 the organization?

12 A Yes.

13 Q You weren't a decision maker for AAPM?

14 A Correct.

15 Q And you played no role in the decisions
16 about, you know, what the content would be for
17 AAPM events, correct?

18 A Correct.

19 Q And you also played no role in any --
20 with respect to deciding the content of any AAPM
21 publications, correct?

22 A Correct.

23 Q And you don't feel qualified to opine on
24 any sort of AAPM messaging. I believe that was

1 the term used before.

2 MS. DICKINSON: Objection. Form.

3 THE WITNESS: I don't remember using the
4 word "opine." I don't feel qualified to assess
5 those statements.

6 BY MS. VICARI:

7 Q And you're not qualified to assess the
8 accuracy of any of AAPM's messaging?

9 MS. DICKINSON: Objection. Form.

10 THE WITNESS: Correct. I don't have any
11 medical training.

12 BY MS. VICARI:

13 Q I just want to turn back to Ms. Torres
14 for a moment. I believe you said that her
15 explanation of why she was contacting you was
16 confusing. Is that the word you used?

17 A I don't remember using that word. It
18 was unclear. When she first contacted me, I
19 didn't have any way to verify her identity, and so
20 I wasn't honestly sure that it was even a
21 legitimate call.

22 Q Did you take steps to try to verify her
23 identity?

24 A No. That was a busy time in my life and

1 I did not.

2 Q Your conversations with Ms. Torres, were
3 they in person or by phone?

4 A By phone.

5 Q Did you ever meet Ms. Torres in person?

6 A No.

7 Q Do you have any understanding of how
8 Ms. Torres received your contact information?

9 A Yes.

10 Q How?

11 A She found me on LinkedIn. I asked her.
12 My -- my -- she called me on my cell phone. I
13 don't know how she got my cell phone number.

14 Q Was your cell phone number included in
15 your LinkedIn profile?

16 A No.

17 Q Did you ever ask her how she got your
18 cell phone number?

19 A No.

20 MS. VICARI: I have no further questions
21 for you.

22 Thank you so much for your time.

23 CROSS-EXAMINATION

24 BY MR. MASTERS:

1 Q Good afternoon, Ms. Tatum. Thank you
2 again for your patience here today.

3 My name is Brad Masters. I represent
4 Cardinal Health, and as she said as well, we've
5 never spoken before, correct?

6 A Correct.

7 Q I just have a couple of very quick
8 questions.

9 Counsel for the plaintiffs asked a
10 number of questions about opioid manufacturers.

11 A Yes.

12 Q Are you familiar with a -- with what a
13 pharmaceutical distributor is?

14 A No. Not as distinct from manufacturer.

15 Q So you don't have any idea of what the
16 role of a pharmaceutical distributor is in the
17 supply chain for opioids?

18 A No.

19 Q And so it's safe to say that you can't
20 recall the names of any pharmaceutical
21 distributors sitting on the Corporate Relations
22 Council, correct?

23 A That's correct. I -- I couldn't
24 distinguish between the two.

1 Q Okay. One last question: How did
2 Ms. Torres respond after you indicated that you
3 wouldn't sign the declaration?

4 A She said she understood and said there
5 was a possibility that I would be served a
6 subpoena.

7 Q And what did you say in response to
8 that?

9 A I said, Okay. I didn't -- there wasn't
10 much to say other than, Okay, if that happens,
11 I'll -- I'll handle it.

12 Q Okay. After she indicated that there's
13 a possibility you would be served with a subpoena,
14 did she ask you to reconsider signing the
15 affidavit?

16 A I don't remember her asking me to
17 reconsider. I made it clear I was not going to
18 sign it.

19 Q Great. Thank you.

20 MR. MASTERS: No further -- no further
21 questions.

22 MS. BAISCH: We will switch again.

23 REDIRECT EXAMINATION

24 BY MS. BAISCH:

1 Q All right, thank you, Elizabeth. Just a
2 couple more things.

3 The reason that you did not sign the
4 declaration sent to you by Ms. Torres was not
5 because it was inaccurate; is that correct?

6 MR. GOLDSTEIN: Object to form.

7 THE WITNESS: I -- when I reviewed it, I
8 saw it in a different way, and I no longer could
9 stand by those statements.

10 BY MS. BAISCH:

11 Q Did you tell Ms. Torres that the AAPM
12 was definitely influenced by the manufacturers?

13 MS. VICARI: Objection to form.

14 THE WITNESS: I may have said something
15 like that to her. Um, I may have said something
16 like that to her.

17 BY MS. BAISCH:

18 Q Did you tell Ms. Torres that you
19 generally recalled that there was a concern among
20 the AAPM board members and staff about the opioid
21 crisis, noting that they saw it coming?

22 MS. VICARI: Objection to form.

23 THE WITNESS: Yeah, that -- that's -- I
24 don't agree with that statement.

1 BY MS. BAISCH:

2 Q Meaning you did not say that to
3 Ms. Torres?

4 A I don't remember saying, "They saw it
5 coming." No, I don't remember that.

6 Q Do you remember saying that there was a
7 concern among the AAPM board members about the
8 opioid crisis?

9 A Yes.

10 Q Do you remember saying that AAPM did not
11 make efforts to curtail the opioid crisis and
12 continued to support the companies who made the
13 opioids?

14 MS. VICARI: Objection. Form.

15 THE WITNESS: Again, I -- I may have
16 said that at one time. That's not the statement
17 I'm making right now.

18 BY MS. BAISCH:

19 Q Did you say that there was no ownership
20 taken by AAPM in terms of ensuring that the risks
21 of opioids were accurately conveyed to
22 prescribers?

23 MS. VICARI: Object to form.

24 THE WITNESS: That may have been a

1 personal opinion that I expressed. Again, as -- I
2 was an administrative assistant. I have no
3 medical training, no grounds on which to assess
4 the decisions of that organization.

5 BY MS. BAISCH:

6 Q But that's a statement you would have
7 made to Ms. Torres?

8 MS. VICARI: Object to form.

9 THE WITNESS: It's possible I said that,
10 yes.

11 MS. BAISCH: I don't have any further
12 questions.

13 MS. DICKINSON: Thank you.

14 THE VIDEOGRAPHER: Okay. The time is
15 1:08 p.m., December 11th, 2018. Going off the
16 record, completing the videotaped deposition.

17 MR. ENGLAND: We're going to read and
18 sign, by the way.

19 (Whereupon, the deposition of

20 ELIZABETH T. TATUM was concluded at

21 1:08 p.m.)
22
23
24

1 CERTIFICATE OF CERTIFIED SHORTHAND REPORTER

2 The undersigned Certified Shorthand Reporter
3 does hereby certify:

4 That the foregoing proceeding was taken before
5 me at the time and place therein set forth, at
6 which time the witness was duly sworn; That the
7 testimony of the witness and all objections made
8 at the time of the examination were recorded
9 stenographically by me and were thereafter
10 transcribed, said transcript being a true and
11 correct copy of my shorthand notes thereof; That
12 the dismantling of the original transcript will
13 void the reporter's certificate.

14 In witness thereof, I have subscribed my name
15 this date: December 13, 2018.

16

17

18 _____
LESLIE A. TODD, CSR, RPR

19 Certificate No. 5129

20 (The foregoing certification of
21 this transcript does not apply to any
22 reproduction of the same by any means,
23 unless under the direct control and/or
24 supervision of the certifying reporter.)

INSTRUCTIONS TO WITNESS

Please read your deposition over carefully and make any necessary corrections. You should state the reason in the appropriate space on the errata sheet for any corrections that are made.

After doing so, please sign the errata sheet and date it.

You are signing same subject to the changes you have noted on the errata sheet, which will be attached to your deposition. It is imperative that you return the original errata sheet to the deposing attorney within thirty (30) days of receipt of the deposition transcript by you. If you fail to do so, the deposition transcript may be deemed to be accurate and may be used in court.

1	-	-	-	-	-	-
2	E	R	R	A	T	A
3	-	-	-	-	-	-

4 PAGE LINE CHANGE

5 _____

6 REASON: _____

7 _____

8 REASON: _____

9. _____

10 REASON: _____

11 _____

12 REASON: _____

13 _____

14 REASON: _____

15 _____

16 REASON: _____

17 _____

18 REASON: _____

19

20 REASON: _____

21

22 REASON:

23

24 REASON:

1 ACKNOWLEDGMENT OF DEPONENT

2 I, _____, do hereby
3 certify that I have read the foregoing pages, and
4 that the same is a correct transcription of the
5 answers given by me to the questions therein
6 propounded, except for the corrections or changes
7 in form or substance, if any, noted in the
8 attached Errata Sheet.

9
10 _____

11 ELIZABETH T. TATUM DATE

12

13

14 Subscribed and sworn to

15 before me this

16 _____ day of _____, 20____.

17 My commission expires: _____

18 _____

19 Notary Public

20

21

22

23

24